

# AUTHOR INDEX

*Arthritis and Rheumatism*, Volume 34, Numbers 1 through 12, 1991

**A**  
 Abadi I, 459  
 Abbink JJ, 1139  
 Abedi-Valugardi M, 1461  
 Abraham D, 1164  
 Abraham GN, 1313  
 Accardo S, 1  
 Adair NE, 1483  
 Adebajo AO, 248  
 Agostoni A, 255  
 Agudelo CA, 118, 1483, 1571  
 Aguilar JL, 1557  
 Agundez A, 304  
 Ahles TA, 15  
 Alarcón GS, 110, 505, 912  
 Alarcon-Segovia D, 1553  
 Albrecht M, 1560  
 Aldag JC, 15  
 Alexander E, 1052  
 Alexander S, 1336  
 Al-Janabi MA, 270  
 Allaire SH, 669  
 Alonso JM, 808  
 Altman HA, 101  
 Altman J, 1052  
 Altman RD, 304, 403, 505  
 Amor B, 198, 1218  
 Andary M, 246  
 Anderson BC, 793  
 Anderson JJ, 669, 1304, 1342  
 Anderson SK, 453  
 Andreu J, 625  
 Andreu JL, 808  
 Annfeld M, 304  
 Anthony JM, 761  
 Appelboom T, 1048  
 Appellrouth D, 505  
 Arasil TK, 789  
 Arimori S, 224  
 Arner EC, 1006  
 Arntz OJ, 606  
 Arstila TP, 89  
 Auquier L, 791  
 Austen KF, 687  
 Aversa JM, 1056  
 Axford JS, 357

**B**  
 Bacon PA, 1151  
 Baglioni P, 1600  
 Bahreman M, 1173  
 Bailey LC, 1151  
 Bakker NPM, 616  
 Balaban EP, 244

Balleari E, 1  
 Ball GV, 782  
 Banquerigo ML, 1282  
 Barash J, 791  
 Barats L, 187  
 Baricchi R, 351  
 Baroja ML, 459  
 Barthelemy CR, 1489  
 Bastide M, 1585  
 Bataille R, 1585  
 Battisto JR, 180  
 Baum J, 128  
 Bell CL, 432  
 Ben-Chetrit E, 1177  
 Bendele AM, 1180  
 Bennett RM, 264  
 Benson MD, 120  
 Ben-Zeev B, 791  
 Bergman A, 561  
 Binder BR, 1430  
 Birnbaum NS, 1209  
 Black C, 1164  
 Blackburn WD Jr., 110, 204, 211  
 Blake DR, 1508  
 Blasini AM, 459  
 Bley L, 1502  
 Bliznak J, 84  
 Bloch DA, 403, 505, 660, 1353  
 Blok D, 442  
 Blotman F, 1487  
 Bocchieri MH, 599  
 Bodman K, 1425  
 Boerbooms AMT, 961  
 Boers M, 501, 1342  
 Boiardi L, 351  
 Boire G, 722  
 Boissier M-C, 790  
 Bollet AJ, 1197  
 Bombardier C, 1268  
 Bombardieri S, 1600, 1606  
 Bomford A, 357  
 Bona CA, 599  
 Bonagura VR, 840  
 Borenstein D, 505  
 Botman CAD, 616  
 Bouanani M, 1585  
 Bouvet J-P, 791  
 Bowness P, 97  
 Boyd RD, 515  
 Brade V, 393  
 Brahn E, 1282  
 Brancós MA, 247  
 Brandt KD, 377, 505, 1381, 1560

Brasington RD Jr., 631  
 Braunstein EM, 377, 1381  
 Brautbar C, 547, 1177  
 Breedveld FC, 442, 822, 831  
 Brewer EJ Jr., 935  
 Bridges AJ, 1116  
 Brinckerhoff CE, 1073  
 Brisson M-L, 220  
 Britton KE, 270  
 Brodeur JP, 1531  
 Brouns MC, 793  
 Brown C, 505  
 Brown DA, 679  
 Brue T, 493  
 Brunden MN, 697  
 Buchanan WW, 192  
 Buchwald D, 1485  
 Budd RC, 537  
 Burckhardt CS, 264  
 Burgess SH, 1391  
 Burgio GR, 1158  
 Burmester GR, 129, 393  
 Burns JC, 126  
 Burr D, 1560  
 Burr DB, 515  
 Buxbaum J, 1553

**C**  
 Cacialli R, 1600  
 Calabrese LH, 257  
 Calin A, 1218  
 Campbell SM, 264  
 Campion GV, 1254  
 Campistol JM, 625  
 Camps J, 253  
 Cañete JD, 247  
 Caporali R, 1487  
 Capozzoli N, 351  
 Carlson M, 246  
 Carlsson B, 1416  
 Carman W, 36  
 Carp HJ, 374  
 Carreno MR, 304  
 Carty TJ, 204  
 Caspi D, 1177  
 Castillo-Ojugas A, 127  
 Castri C, 351  
 Cathey MA, 951  
 Cats A, 822, 1218  
 Chambourlier P, 493  
 Chang RW, 856  
 Chard MD, 766  
 Chatham WW, 211  
 Chen M, 1116  
 Chertok P, 1487

Cheung HS, 904, 1021  
 Chiaravalloti F, 351  
 Chin JE, 78, 314, 697, 1245  
 Chmielewski WL, 1571  
 Chu CQ, 1125  
 Chuck A, 1297  
 Cid MC, 1557  
 Claman HN, 1495  
 Clark SR, 264  
 Clayburne G, 118  
 Cleland LG, 1039  
 Clements PJ, 1371  
 Clot J, 246  
 Clough JD, 146, 1624  
 Cloutier J-M, 153  
 Coblyn J, 481  
 Coddling C, 1340  
 Cohen MG, 787  
 Cohen SB, 252  
 Cole BC, 468  
 Cole E, 1268  
 Colette C, 1487  
 Collado A, 247, 625  
 Combe B, 246  
 Concannon P, 1260  
 Condemi JJ, 1313  
 Condie RM, 244  
 Connell KJ, 234  
 Conover J, 1404  
 Cooke TD, 505  
 Cooper PH, 325  
 Cooper SM, 537  
 Coulton L, 287  
 Cowchock FS, 375  
 Craft J, 731  
 Criswell LA, 934  
 Croft JD, 1209  
 Crouzel C, 198  
 Crow MK, 468  
 Cugno M, 255  
 Cush JJ, 120  
 Cutolo M, 1  
 Czop JK, 687

**D**  
 Daha MR, 442, 831  
 Dalakas MC, 1391  
 Daling JR, 1502  
 Daltroy LH, 234, 1187  
 D'Amato J, 822  
 Dang H, 1336  
 Danho W, 572  
 Daniel WW, 125, 505  
 Danieli G, 375  
 Daniels L, 68  
 Dankó K, 933

# AUTHOR INDEX

*Arthritis and Rheumatism*, Volume 34, Numbers 1 through 12, 1991

**A**  
 Abadi I, 459  
 Abbink JJ, 1139  
 Abedi-Valugardi M, 1461  
 Abraham D, 1164  
 Abraham GN, 1313  
 Accardo S, 1  
 Adair NE, 1483  
 Adebajo AO, 248  
 Agostoni A, 255  
 Agudelo CA, 118, 1483, 1571  
 Aguilar JL, 1557  
 Agundez A, 304  
 Ahles TA, 15  
 Alarcón GS, 110, 505, 912  
 Alarcon-Segovia D, 1553  
 Albrecht M, 1560  
 Aldag JC, 15  
 Alexander E, 1052  
 Alexander S, 1336  
 Al-Janabi MA, 270  
 Allaire SH, 669  
 Alonso JM, 808  
 Altman HA, 101  
 Altman J, 1052  
 Altman RD, 304, 403, 505  
 Amor B, 198, 1218  
 Andary M, 246  
 Anderson BC, 793  
 Anderson JJ, 669, 1304, 1342  
 Anderson SK, 453  
 Andreu J, 625  
 Andreu JL, 808  
 Annfeld M, 304  
 Anthony JM, 761  
 Appelboom T, 1048  
 Appellrouth D, 505  
 Arasil TK, 789  
 Arimori S, 224  
 Arner EC, 1006  
 Arntz OJ, 606  
 Arstila TP, 89  
 Auquier L, 791  
 Austen KF, 687  
 Aversa JM, 1056  
 Axford JS, 357

**B**  
 Bacon PA, 1151  
 Baglioni P, 1600  
 Bahreman M, 1173  
 Bailey LC, 1151  
 Bakker NPM, 616  
 Balaban EP, 244

Balleari E, 1  
 Ball GV, 782  
 Banquerigo ML, 1282  
 Barash J, 791  
 Barats L, 187  
 Baricchi R, 351  
 Baroja ML, 459  
 Barthelemy CR, 1489  
 Bastide M, 1585  
 Bataille R, 1585  
 Battisto JR, 180  
 Baum J, 128  
 Bell CL, 432  
 Ben-Chetrit E, 1177  
 Bendele AM, 1180  
 Bennett RM, 264  
 Benson MD, 120  
 Ben-Zeev B, 791  
 Bergman A, 561  
 Binder BR, 1430  
 Birnbaum NS, 1209  
 Black C, 1164  
 Blackburn WD Jr., 110, 204, 211  
 Blake DR, 1508  
 Blasini AM, 459  
 Bley L, 1502  
 Bliznak J, 84  
 Bloch DA, 403, 505, 660, 1353  
 Blok D, 442  
 Blotman F, 1487  
 Bocchieri MH, 599  
 Bodman K, 1425  
 Boerbooms AMT, 961  
 Boers M, 501, 1342  
 Boiardi L, 351  
 Boire G, 722  
 Boissier M-C, 790  
 Bollet AJ, 1197  
 Bombardier C, 1268  
 Bombardieri S, 1600, 1606  
 Bomford A, 357  
 Bona CA, 599  
 Bonagura VR, 840  
 Borenstein D, 505  
 Botman CAD, 616  
 Bouanani M, 1585  
 Bouvet J-P, 791  
 Bowness P, 97  
 Boyd RD, 515  
 Brade V, 393  
 Brahn E, 1282  
 Brancós MA, 247  
 Brandt KD, 377, 505, 1381, 1560

Brasington RD Jr., 631  
 Braunstein EM, 377, 1381  
 Brautbar C, 547, 1177  
 Breedveld FC, 442, 822, 831  
 Brewer EJ Jr., 935  
 Bridges AJ, 1116  
 Brinckerhoff CE, 1073  
 Brisson M-L, 220  
 Britton KE, 270  
 Brodeur JP, 1531  
 Brouns MC, 793  
 Brown C, 505  
 Brown DA, 679  
 Brue T, 493  
 Brunden MN, 697  
 Buchanan WW, 192  
 Buchwald D, 1485  
 Budd RC, 537  
 Burckhardt CS, 264  
 Burgess SH, 1391  
 Burgio GR, 1158  
 Burmester GR, 129, 393  
 Burns JC, 126  
 Burr D, 1560  
 Burr DB, 515  
 Buxbaum J, 1553

**C**  
 Cacialli R, 1600  
 Calabrese LH, 257  
 Calin A, 1218  
 Campbell SM, 264  
 Campion GV, 1254  
 Campistol JM, 625  
 Camps J, 253  
 Cañete JD, 247  
 Caporali R, 1487  
 Capozzoli N, 351  
 Carlson M, 246  
 Carlsson B, 1416  
 Carman W, 36  
 Carp HJ, 374  
 Carreno MR, 304  
 Carty TJ, 204  
 Caspi D, 1177  
 Castillo-Ojugas A, 127  
 Castri C, 351  
 Cathey MA, 951  
 Cats A, 822, 1218  
 Chambourlier P, 493  
 Chang RW, 856  
 Chard MD, 766  
 Chatham WW, 211  
 Chen M, 1116  
 Chertok P, 1487

Cheung HS, 904, 1021  
 Chiaravalloti F, 351  
 Chin JE, 78, 314, 697, 1245  
 Chmielewski WL, 1571  
 Chu CQ, 1125  
 Chuck A, 1297  
 Cid MC, 1557  
 Claman HN, 1495  
 Clark SR, 264  
 Clayburne G, 118  
 Cleland LG, 1039  
 Clements PJ, 1371  
 Clot J, 246  
 Clough JD, 146, 1624  
 Cloutier J-M, 153  
 Coblyn J, 481  
 Coddling C, 1340  
 Cohen MG, 787  
 Cohen SB, 252  
 Cole BC, 468  
 Cole E, 1268  
 Colette C, 1487  
 Collado A, 247, 625  
 Combe B, 246  
 Concannon P, 1260  
 Condemi JJ, 1313  
 Condie RM, 244  
 Connell KJ, 234  
 Conover J, 1404  
 Cooke TD, 505  
 Cooper PH, 325  
 Cooper SM, 537  
 Coulton L, 287  
 Cowchock FS, 375  
 Craft J, 731  
 Criswell LA, 934  
 Croft JD, 1209  
 Crouzel C, 198  
 Crow MK, 468  
 Cugno M, 255  
 Cush JJ, 120  
 Cutolo M, 1  
 Czop JK, 687

**D**  
 Daha MR, 442, 831  
 Dalakas MC, 1391  
 Daling JR, 1502  
 Daltroy LH, 234, 1187  
 D'Amato J, 822  
 Dang H, 1336  
 Danho W, 572  
 Daniel WW, 125, 505  
 Danieli G, 375  
 Daniels L, 68  
 Dankó K, 933

Danon YL, 973  
 Dansette PM, 1594  
 Darling JM, 1076  
 Dauphinée MJ, 1336  
 Davis JS IV, 1133  
 Davis LS, 1274  
 Dawkins R, 224  
 Day RO, 751  
 Dean DD, 304  
 Dearden A, 97  
 De Benedetti F, 1158  
 De Broe M, 287  
 De Maertelaer V, 1048  
 De Médicis R, 333  
 De Paulis A, 1289  
 Depper J, 561  
 De Prez E, 1048  
 De Rooy D-JRAM, 961  
 De Rooy HH, 831  
 Deschodt-Lanckman M, 1048  
 De Visser H, 1611  
 De Waal LP, 486  
 Didry C, 246  
 Dieppe PA, 1254  
 Dier DL, 537  
 Dijkmans B, 1218  
 Disdier P, 493  
 Dobrinich R, 1031  
 Doesburg WH, 961  
 Doherty M, 1297  
 Doherty SM, 287  
 Dolan PW, 164  
 Dore RK, 1209  
 Dougados M, 1218  
 Doyle DV, 270  
 Dreyfus P, 790  
 Druet E, 1594  
 Druet P, 1594  
 Duboc D, 198  
 Dugowson CE, 1502  
 Dunne R, 561

## E

Earnshaw W, 68  
 Easley K, 257  
 Edelman P, 856  
 Edelson RL, 646  
 Egger MJ, 502  
 Eguchi K, 296  
 Ehresmann GR, 920  
 Elford PR, 325  
 Elkayam O, 1177  
 Elkon KB, 572  
 Emery P, 127  
 Emmrich F, 129  
 Engber W, 1116  
 Engle E, 937  
 Enzenauer RJ, 1344  
 Epstein WV, 501  
 Ercilla MG, 247

Escalante A, 920  
 Eskra JD, 204  
 Evans J, 731  
 Evans WE, 1514  
 Evers-Schouten JH, 442  
 Ezaki I, 343

## F

Fam AG, 241  
 Farewell VT, 1268  
 Fassbender H-G, 1444  
 Faulkes DJ, 119  
 Faure M-P, 153  
 Feldman D, 505  
 Feldmann M, 1125  
 Felson DT, 499, 1209, 1304, 1342  
 Fernandez-Viña M, 1310  
 Ferrante A, 1452  
 Ferri C, 1606  
 Field M, 1125  
 Fife RS, 377, 1381  
 Filie JD, 1466  
 Finck D, 121  
 Finegan CK, 383  
 Finn S, 84  
 Firestein GS, 1094  
 Fleischmann RM, 252  
 Fleming RA, 1514  
 Fleming WE, 1245  
 Fletcher EM, 552  
 Fortin PR, 228  
 Fosella PV, 1606  
 Fournie A, 1069  
 Fox DA, 561  
 Fox RI, 1617  
 Franssen MJAM, 961  
 Fredens K, 414  
 Freundlich B, 1319  
 Friedman CP, 234  
 Friedman SM, 468  
 Frieler M, 580  
 Fries JF, 984, 1353  
 Fujita N, 296  
 Fukuda T, 296  
 Fukui N, 343  
 Furst DE, 931, 1371

## G

Gabrielli A, 375  
 Galloway J, 287  
 Galper SR, 1187  
 Gao X, 547, 1310  
 Garcia N, 253  
 García-de la Torre I, 744  
 Garry RF, 1336  
 Gaston JSH, 1151  
 Gaucher A, 737  
 Gaus W, 1621  
 Gay RE, 1444  
 Gay S, 1444

Gazit E, 374, 547  
 Gemignani G, 788  
 Genovese M, 937  
 Georgilis K, 770  
 Geppert TD, 244  
 Germain BF, 1514  
 Gerrits-Boeye MY, 1611  
 Giannini EH, 935  
 Gilbert C, 333  
 Gillet P, 737  
 Ginsburg KS, 1624  
 Ginsburg WW, 1185  
 Giorno RC, 1495  
 Giusti M, 1  
 Gladman DD, 192, 1268  
 Glickman P, 799  
 Glimcher LH, 1076  
 Goldberg RL, 799  
 Goldman JA, 1207  
 Gorevic PD, 1313  
 Goto K, 243  
 Goyal S, 1425  
 Graham S, 751  
 Granados J, 1553  
 Granfors K, 89  
 Gratacós J, 625  
 Grau JM, 1557  
 Gravalles EM, 1076  
 Gray RES, 287  
 Graziano FM, 432, 1116  
 Greco F, 1606  
 Green D, 192  
 Greenberg CS, 996  
 Greenwald R, 505  
 Greenwood A, 270  
 Gregoir C, 1207  
 Grimard M, 333  
 Grinlinton FM, 916  
 Grisoli F, 493  
 Gruber BL, 362  
 Guérin F, 198  
 Guery J-C, 1594  
 Gunnia UB, 55  
 Gustafsson R, 414  
 Guyatt GH, 1342

## H

Hack CE, 1139  
 Hader N, 866  
 Hadler NM, 634  
 Hale LP, 1434  
 Halla JT, 84  
 Hällgren R, 414  
 Halma C, 442  
 Hamilton E, 1297  
 Hamilton EBD, 357  
 Hammer M, 423  
 Hanuryudan V, 1071  
 Handel M, 751  
 Hara M, 1546  
 Harada Y, 48  
 Haraoui B, 153  
 Hardin JG, 84, 1069  
 Harigai M, 1546  
 Harle J-R, 493  
 Harley JB, 1052  
 Hart BA, 616  
 Hart HH, 916  
 Hartner S, 873  
 Hasty KA, 776  
 Hatam L, 840  
 Hatfield CA, 314, 1245  
 Hauzeur J-P, 1048  
 Haverman JF, 961  
 Hawley IC, 97  
 Hawrylko E, 580  
 Hawthorne VM, 36  
 Haynes BF, 1434  
 Hazenberg MP, 1611  
 Hazes JMW, 499, 822  
 Hazleman BL, 766  
 Hazleman R, 766  
 Healey LA, 120  
 Heck LW, 204, 211  
 Hedfors E, 1070  
 Heiskanen A, 815  
 Hekim H, 1071  
 Helfgott S, 481  
 Heve T, 815  
 Hendrich C, 423  
 Henke CJ, 501  
 Henriksen PD, 599  
 Herblin WF, 314  
 Herborn G, 1236  
 Hermans J, 442  
 Hernandez RJ, 1580  
 Hernández-Vazquez L, 744  
 Herrmann K, 375  
 Hester GG, 552  
 Hewett JE, 453  
 Higaki M, 714  
 Hildebrandt S, 68  
 Hillert J, 1416  
 Hilliquin P, 1207  
 Hines JJ, 572  
 Hirohata S, 1620  
 Hirose T, 1546  
 Ho E, 187  
 Hoch S, 126  
 Hochberg MC, 373, 505, 639, 937  
 Hoffman GS, 1466  
 Hoffman RW, 453  
 Hofschneider PH, 1621  
 Holman HR, 1187  
 Holoshitz J, 679  
 Horneff G, 129  
 Hosking D, 1297  
 Hovestadt A, 1397  
 Howard B, 241  
 Howard D, 1538  
 Howe S, 873

Howell DS, 304, 505  
 Hoy MDS, 639  
 Huff JP, 799  
 Hughes R, 588  
 Hughes SL, 856  
 Huitfeldt B, 1218  
 Hull AL, 234  
 Hulman JF, 1180  
 Huskisson EC, 270  
 Hutt-Fletcher LM, 846

# I

Ichikawa Y, 224  
 Ida H, 296  
 Ike R, 505  
 Ingram SB, 264  
 Inoue T, 1620  
 Intra E, 1  
 Irvin WS, 453  
 Isenberg D, 1425  
 Ishigatsubo Y, 1404  
 Ishimaru T, 296  
 Ishizuka T, 1546  
 Isphording W, 1069  
 Ito K, 1620  
 Itoh Y, 888

# J

Jaquet P, 493  
 Jarjour WN, 1133  
 Jeffries BD, 1133  
 Jeurissen MEC, 961  
 Jicinsky J, 1116  
 Jimenez SA, 599  
 Joffe MM, 1391  
 Johnson LS, 1521  
 Jones AKP, 270  
 Jonker M, 616  
 Joyal F, 68  
 Juhlin R, 1218  
 Jundt JW, 217  
 Justen JM, 78, 697

# K

Kahaleh MB, 978  
 Kahan A, 198  
 Kakavand B, 525  
 Kalasinski LA, 377  
 Kalden JR, 129, 393  
 Kallman D, 639  
 Kamp AM, 1139  
 Kanda H, 343  
 Kanis JA, 287  
 Kapila P, 505  
 Kaplan D, 505  
 Kaplan H, 497, 1209  
 Kaplan SS, 101  
 Karger T, 1236  
 Kashiwagi H, 243

Kashiwazaki S, 171  
 Kasturi KN, 599  
 Katz BP, 377, 1381  
 Katz J, 1325  
 Katz JN, 1076, 1228, 1624  
 Katz PP, 934, 1361  
 Katz R, 799  
 Kaufman LD, 362  
 Kaufman RL, 1209  
 Kawagoe M, 1546  
 Kawaguchi Y, 1546  
 Kawakami A, 296  
 Kay J, 687  
 Kazis LE, 761  
 Keat A, 588  
 Keim DR, 1580  
 Kelley DM, 257  
 Kerr GS, 1466  
 Khorasani R, 1387  
 Khraishi M, 241  
 Kijlstra A, 486  
 Kimura M, 171  
 Kimura O, 371  
 Kinarty A, 866  
 King RH, 766  
 Kingsley G, 588  
 Kirchheimer JC, 1430  
 Kitajima I, 714  
 Kitani A, 1546  
 Klashman DJ, 276  
 Klempner MS, 770  
 Klinman DM, 1404  
 Kobayashi S, 48  
 Koepsell TD, 1502  
 Kolanus W, 423  
 Kolarz G, 1205  
 Komaroff AL, 1485  
 Kool J, 1611  
 Koopman WJ, 120, 505  
 Korn JH, 1164  
 Kornguth S, 432  
 Kosek J, 679  
 Kotowicz MA, 1488  
 Kowanko IC, 1452  
 Krause A, 393  
 Krieg T, 375  
 Krüger K, 525  
 Kruijsen MWM, 961  
 Krzesicki RF, 314, 1245  
 Kuipers JG, 423  
 Kumar A, 1553  
 Kumar P, 1553  
 Kurata A, 296  
 Kurki P, 815  
 Kurosawa S, 371  
 Kurouji K, 296  
 Kushner I, 1065

# L

Lachenbruch PA, 1371  
 Ladd AL, 1076  
 Lahat N, 866  
 Lähdevirta J, 6  
 Lahesmaa R, 89  
 Laing TJ, 234  
 Lakhonpal S, 252  
 Langevitz P, 123  
 Lapointe S, 722  
 Larson MG, 1624  
 Lassoued S, 1069  
 Lauhio A, 6  
 Lavery JP, 1484  
 Lavie P, 655  
 Laxer RM, 1575  
 Leff RL, 1391  
 Lefrère J-J, 790  
 Leigh JP, 984  
 Leirisalo-Repo M, 6, 815  
 Lemmel EM, 1621  
 Lenz ME, 799, 1254  
 Leoni P, 375  
 Leon-Ponte M, 459  
 Leroux JL, 1487  
 Leventhal LJ, 1319  
 Levick JR, 1508  
 Levine S, 63  
 Levinson J, 873  
 Li EK, 787  
 Liang MH, 228, 1187, 1228  
 Life PF, 1151  
 Limburg PC, 1206  
 Lindahl G, 1070  
 Lindsley CB, 106  
 Ling Q, 1466  
 Lipsky PE, 120, 244, 1274, 1476  
 Lisse JR, 1484  
 Littman BH, 1094  
 Livneh A, 547, 973  
 Llana J, 625  
 Loc'h C, 198  
 Lomeña F, 625  
 Longombardo G, 1606  
 Loose LD, 204, 211  
 Lopez-Longo F-J, 722  
 López-Méndez A, 912  
 Lorber M, 655  
 Lorenz R, 481  
 Louie DC, 228  
 Louisot P, 1332  
 Loutis N, 776  
 Love LA, 1391  
 Lovell D, 873  
 Lukoschek M, 515  
 Lupoli S, 1164, 1289  
 Lussier A, 333  
 Lynch NM, 916

# M

Macchioni P, 351  
 MacFadden DK, 1329  
 Machtey I, 1205  
 Madan ME, 304  
 Maguire L, 123  
 Maier A, 481  
 Maier D, 1231  
 Maini RN, 1125  
 Malawista SE, 646  
 Malhotra U, 1260  
 Malone C, 846  
 Malone DG, 164, 1116  
 Mandet C, 1594  
 Manthey R, 793  
 Mantovani W, 351  
 Manzi S, 101  
 Marasini B, 255  
 Marder WD, 1209  
 Maria-Forte A, 1553  
 Marini JC, 1466  
 Marino C, 505  
 Marks CR, 43  
 Marone G, 1289  
 Marsh JD, 228  
 Martel-Pelletier J, 153  
 Martínez-A C, 808  
 Martínez-Maza O, 276  
 Martínez-Tarquino C, 1553  
 Martin J, 894  
 Martin ME, 1434  
 Martin RA, 276  
 Martini A, 1158  
 Maruyama I, 714  
 Maruyama Y, 714  
 Marzo E, 1606  
 Masaki T, 243  
 Masi AT, 15  
 Massa M, 1158  
 Mathieu P, 1332  
 Matsuki Y, 1546  
 Matsuoka A, 22  
 Matsushima K, 894  
 Mayrhofer G, 1039  
 Maziere B, 198  
 Mazur P, 121  
 Mazzuca SA, 234  
 McBroom PC, 552  
 McCachren SS, 1085  
 McCallum RM, 1434  
 McCarthy GM, 1021, 1489  
 McCarty GA, 1340  
 McCrae F, 1254  
 McCune AB, 101  
 McCune WJ, 561  
 McCusker CT, 192  
 McDonald E, 505  
 McGirr G, 873  
 McGrath H Jr., 498

McKnight KM, 118, 1483, 1571  
 McLaughlin J, 1268  
 McShane DJ, 505  
 McWhirter A, 1164  
 Medsger TA Jr., 101, 403, 505, 1336  
 Meenan RF, 499, 669, 761, 1209, 1304, 1342  
 Mehraban F, 383  
 Mele CA, 580  
 Ménard H-A, 722  
 Menkès CJ, 198, 1207  
 Merry P, 1508  
 Michalek JE, 552  
 Michalski JP, 1069  
 Michel BA, 403, 505  
 Migita K, 296  
 Millard JA, 561  
 Miller FW, 1391  
 Mimura T, 1133  
 Miner PB Jr., 106  
 Mitchell DM, 660  
 Mitchell PG, 1021  
 Mitrovic DR, 638  
 Miyasaka N, 714  
 Miyauchi T, 243  
 Mock D, 217  
 Möller E, 1461  
 Moller PW, 639  
 Montecucco C, 1487  
 Morales S, 304  
 Moreau P, 737  
 Moreland LW, 782  
 Moretti A, 1606  
 Moriuchi J, 224  
 Moriya H, 48  
 Morohoshi Y, 171  
 Morris EL, 1052  
 Morris T, 97  
 Moses H, 1052  
 Moskowitz RW, 383  
 Moxley G, 1531  
 Mudge GH Jr., 228  
 Mulder J, 961  
 Mulero J, 808  
 Muller WH, 961  
 Muniz OE, 304  
 Muñoz-Gómez J, 247, 625  
 Murphy G, 228  
 Murphy WA, 505  
 Muryoi T, 599  
 Muskiet FAJ, 1206  
 Myers A, 257  
 Myers SL, 1560  
 Myerson G, 1207

**N**

Naccache PH, 333  
 Nagataki S, 296

Nagel JS, 1387  
 Nahir M, 655  
 Naides SJ, 1319  
 Nakajima Y, 714  
 Nakamura H, 1546  
 Nakamura K, 171  
 Nakano T, 171  
 Nakao H, 296  
 Nanishi F, 180  
 Naparstek Y, 547  
 Nelson DL, 264  
 Nelson JL, 1502  
 Nepom BS, 43, 1260  
 Nepom GT, 43  
 Nettelbladt O, 414  
 Nettles JW, 43, 1260  
 Neustadt DH, 923  
 Nicklas JA, 537  
 Nieuwenhuys EJ, 1139  
 Nishikai M, 791  
 Nishioka K, 714  
 Nobunaga M, 343  
 Noell S, 68  
 Noring R, 770  
 Nossent JC, 1397  
 Nuijens JH, 1139

# O

Oberly EH, 490  
 O'Connell M, 257  
 O'Donnell JL, 639  
 Oksman F, 1069  
 Olerup O, 1416  
 Olivier I, 788, 1218  
 Olken D, 121  
 Olsen I, 1164  
 Olsen NJ, 187, 1310  
 Orgad S, 374  
 Ortiz-Bravo E, 1466  
 Ory P, 1116  
 Osame M, 714  
 Osial T, 505  
 Østensen M, 881  
 Oster N, 580  
 Otten HG, 831  
 Oxman AD, 1342  
 Özbakir F, 1071

# P

Padeh S, 1575  
 Pages M, 1069  
 Paimela L, 815  
 Paine MM, 1094  
 Palacios-Boix A, 588  
 Palchik NS, 234  
 Palla P, 1606  
 Panayi GS, 588  
 Pandey JP, 453, 1553  
 Paolaggi J-B, 791

Papsidero L, 1313  
 Parke AL, 1231, 1325  
 Parker S, 1069  
 Partington C, 432  
 Partridge AJ, 1187  
 Pascual E, 141  
 Pasero G, 788, 1218, 1606  
 Pasquier R, 1594  
 Patton KL, 1434  
 Pau B, 1585  
 Paulus HE, 502, 931, 1371, 1619  
 Pauwels EKJ, 442  
 Peacock DJ, 1282  
 Pelletier J-P, 153  
 Pelletier L, 1594  
 Pere P, 737  
 Perhala RS, 146, 1624  
 Perl A, 1313  
 Perrier P, 737  
 Peterson MGE, 502  
 Petri M, 937, 1538  
 Peveri P, 894  
 Piechaczyk M, 1585  
 Piela TH, 1164  
 Pincus T, 1310  
 Phippen AMM, 996  
 Pitzalis C, 588  
 Plater-Zyberk C, 1164  
 Plotz PH, 1391  
 Poiesz BJ, 1313  
 Poole CA, 22  
 Porter JM, 264  
 Portioli I, 351  
 Posnett DN, 468  
 Postlethwaite AE, 120  
 Poubelle PE, 333  
 Pras M, 973  
 Pratta MA, 1006  
 Prieto J, 253  
 Provost TT, 1052

# Q

Quismorio FP Jr., 920

# R

Racadot E, 1622  
 Rachow JW, 1014  
 Radin EL, 515  
 Rahn DW, 1056  
 Ramírez-Casillas A, 744  
 Ramsey-Goldman R, 101, 505  
 Rasker JJ, 961  
 Rau R, 1236  
 Ravelli A, 1158  
 Raymond Y, 249  
 Recklies AD, 1106  
 Reichlin M, 888, 1052, 1209

Reid B, 192  
 Reife RA, 776  
 Reinhardt BN, 707  
 Reiss BB, 766  
 Reiter C, 525  
 Reme T, 246  
 Remold HG, 1430  
 Renoux M, 1207  
 Repke J, 1538  
 Repo H, 6  
 Reuben A, 731  
 Revell P, 357  
 Revell PA, 1508  
 Reynolds WJ, 1329  
 Richard M, 1332  
 Rickman LS, 1339  
 Ridderstad A, 1461  
 Rieber EP, 525  
 Riethmüller G, 525  
 Riggs BL, 1488  
 Rimon D, 866  
 Robbins M, 432  
 Robbioni P, 1158  
 Roberge CJ, 333  
 Roberts FK, 951  
 Rodriguez MA, 459  
 Rodriguez I, 304  
 Roessner KD, 537  
 Rohloff NA, 697  
 Roitt I, 1425  
 Rosenthal AK, 904  
 Rossi B, 1337  
 Rossi F, 351  
 Roth SH, 496  
 Rothfield NF, 68  
 Rothschild B, 505  
 Roussin A, 68  
 Rubio N, 126  
 Ruddy S, 1531  
 Ruju G, 788  
 Ruppel PL, 697  
 Ruseler-van Embden JGH, 1611  
 Russell IJ, 552  
 Ryan LM, 904  
 Ryan S, 377

# S

Sagawa A, 371  
 Saikku P, 6  
 Sakai K, 343  
 Salhi SL, 1585  
 Saltzman A, 63  
 Salvarani C, 351  
 Sam LM, 78, 697  
 Sanders KM, 498  
 Sanders ME, 1245  
 Sangro B, 253  
 Sanmarti R, 247



San Miguel VV, 1484  
 Santoro D, 894  
 Sany J, 246  
 Sato A, 791  
 Sato K, 714  
 Sawada T, 1620  
 Schaller JG, 1260  
 Scharf Y, 655  
 Schattenkirchner M, 525  
 Scherak O, 1205  
 Schiftenbauer J, 1411  
 Schmidt RE, 423  
 Schnitzer TJ, 1254  
 Schoen RT, 1056  
 Schoerner C, 393  
 Schofield JR, 22  
 Schönfeld DHW, 1397  
 Schreuder GMT, 822  
 Schrohenloher RE, 120  
 Schuette P, 856  
 Schulte M, 873  
 Schumacher HR Jr., 118,  
 1173, 1466  
 Schur PH, 1204, 1553  
 Schwartz LB, 1531  
 Schwarz DA, 1260  
 Sciuto M, 1337  
 Scott WW Jr., 639  
 Seebach JS, 164  
 Segal AM, 146, 246, 1624  
 Segal R, 547, 1177  
 Seibold JR, 55, 1336, 1495  
 Seleznick MJ, 1514  
 Senécal J-L, 68, 249  
 Sharp GC, 453  
 Sharp JT, 660  
 Shear E, 873  
 Shelbourne KD, 377  
 Shimizu H, 224  
 Shingu M, 343  
 Shirai A, 1404  
 Sibley R, 679  
 Sieper J, 588  
 Sigal LH, 367  
 Silverman ED, 1575  
 Silverman GJ, 935  
 Silver MM, 1575  
 Sinclair H, 1425  
 Singal DP, 192  
 Singer RH, 856  
 Sixou L, 1069  
 Skurnik M, 89  
 Small P, 220  
 Smith JB, 375  
 Smith RJ, 78, 697  
 Sobnack R, 270  
 Sohar E, 973  
 Solanki K, 270  
 Solbach W, 393  
 Sowers MF, 36  
 Spadaro G, 1289

Spagnuolo PJ, 1031  
 Spector TD, 373  
 Sperling R, 481  
 Spertus A, 580  
 Spragg J, 481  
 Stastny P, 547, 1310  
 Stedford J, 933  
 Steere AC, 707, 770, 1056  
 Steinberg AD, 945, 1404  
 Steinberg SC, 945  
 Stekman IL, 459  
 Stern S, 228  
 Sterz MG, 1371  
 Stevens CR, 1508  
 Stevens RH, 276  
 Stewart CF, 1514  
 Stewart K, 246  
 Sthoeger D, 791  
 Stobo JD, 641, 1209  
 Straaton KV, 912, 1187  
 Strauch G, 198  
 Strober S, 679  
 Ström H, 1416, 1461  
 Stuart JM, 776  
 Subira ML, 253  
 Sullivan DB, 1580  
 Sumar N, 1425  
 Suzuki K, 1546  
 Suzuki N, 243  
 Swaak AJG, 1139, 1397  
 Syrota A, 198  
 Szegedi G, 933

# T

Tack BB, 934  
 Takagishi K, 171  
 Takaya M, 224  
 Talal N, 1336  
 Taniguchi M, 48  
 Tao X, 1274  
 Targoff IN, 1340, 1391  
 Taurog JD, 1476  
 Tavoni A, 1600  
 Terato K, 48  
 Terkeltaub R, 894  
 Thomas T, 55  
 Thomas TJ, 55  
 Thonar EJ-MA, 799, 1254  
 Thorpe-Swenson AJ, 631  
 Tirri G, 1289  
 Tobin JD, 639  
 Toivanen P, 89  
 Tosun M, 789  
 Tournade H, 1594  
 Trabandt A, 1444  
 Treharne J, 588  
 Treisman J, 561  
 Trentham DE, 1466  
 Trock DH, 646  
 Trujillo A, 808  
 Tsokos MG, 1466

Tsuchiya N, 846  
 Tsuji K, 224  
 Tsukamoto Y, 171  
 Tulgan H, 121  
 Tulleken JE, 1206  
 Tumang JR, 468  
 Tumeh SS, 481, 1387  
 Tuncer S, 789  
 Turski P, 432

# U

Uedelhoven WM, 481  
 Ueki Y, 296  
 Urbach AH, 101  
 Urbano-Márquez A, 1557  
 Urowitz MB, 123, 1268

# V

Valentini G, 1289  
 Vallee C, 1207  
 Van Beuningen HM, 606  
 Van Beusekom HJ, 961  
 Van de Putte LBA, 124,  
 961  
 Van den Berg WB, 606,  
 1611  
 Van den Hoogen FHJ, 490  
 Van der Heijde DMFM,  
 124  
 Van der Linden SM, 486,  
 1218  
 Van Erck MGM, 616  
 Van Es LA, 442  
 Van Eys GJJM, 486  
 Van Laar JM, 831  
 Van Lieshout LMC, 1611  
 Van Riel PLCM, 124  
 Van Rijswijk MH, 1206  
 Van't Hof MA, 124  
 Van Venrooij WJ, 490  
 Van Zeben D, 822  
 Verbsky JW, 164  
 Verheijen R, 490  
 Verjans GMGM, 486  
 Veum JA, 1014, 1489  
 Veys E, 1218  
 Vial M-C, 1594  
 Viel JF, 1622  
 Vignon E, 1332  
 Viitanen A-M, 89  
 Vikingsson A, 164  
 Viner NJ, 1151  
 Vinetz JM, 1339  
 Vitali C, 1337, 1600  
 Vivaldi I, 1600  
 Voigt LF, 1502  
 Volastro P, 121  
 Vu VD, 737

# W

Wakisaka A, 224  
 Walker ER, 515  
 Wallace DJ, 372  
 Wallin B., 761  
 Wallin J, 1416  
 Walport MJ, 97  
 Waiz-LeBlanc BAE, 1329  
 Wanivenhaus A, 1430  
 Ward JR, 502  
 Watanabe T, 343  
 Watson WC, 776  
 Watt I, 357  
 Weber P, 481  
 Wedgwood JF, 840  
 Wegrzyn L, 1411  
 Weiller P-J, 493  
 Weinberg JB, 996  
 Weinblatt M, 481  
 Weiner ES, 68  
 Weinstein A, 1343  
 Weisman MH, 931  
 Weissfeld L, 36  
 Weissman BN, 1061  
 Welch WJ, 1133  
 Wendling D, 1622  
 Wener MH, 1485  
 Werdier D, 1236  
 Weryha G, 737  
 West SG, 1344  
 Westmark KD, 1061  
 White C, 1106  
 White CS, 246  
 Wieslander J, 375  
 Wigley FM, 639  
 Wilke WS, 146, 1624  
 Williams CA, 1353  
 Williams HJ, 502  
 Williams KM, 751  
 Williams PG, 502  
 Williams R, 357  
 Williams RC Jr., 846  
 Willkens RF, 43  
 Wilson D, 1231  
 Winfield JB, 1133  
 Winterrowd GE, 1245  
 Wise CM, 1571  
 Woessner JF Jr., 927  
 Wolfe F, 505, 660, 951  
 Woo P, 119  
 Wordsworth BP, 933  
 Wortmann RL, 1014, 1489  
 Wu DD, 515

# Y

Yamamoto K, 714  
 Yamane K, 243  
 Yamase H, 1325  
 Yanagisawa M, 243

Yanch JC, 1521  
Yaron M, 1177  
Yazici H, 1071  
Yelin EH, 1361  
York JC, 1484

Yoshinari NH, 707  
Yoshino S, 1039  
Young A, 1425  
Yunus MB, 15  
Yurdakul S, 1071

Z  
Zachariae C, 894  
Zashin SJ, 244  
Zeidler H, 1218  
Zeldes W, 561

Zemer D, 973  
Ziff M, 1345  
Zizzi F, 351  
Zobel D, 36  
Zwinderman AH, 822

## SUBJECT INDEX

*Arthritis and Rheumatism*, Volume 34, Numbers 1 through 12, 1991

### A

- Abortion, recurrent spontaneous
  - anti-paternal antibodies and, 374
  - antiphospholipid antibodies in, 1231
- Achromobacter xylosoxidans*, septic arthritis, in SLE, 1484
- Acquired immunodeficiency syndrome (AIDS)
  - Mycobacterium avium* complex-induced chronic arthritis in, 1339
  - SLE and, 372
- 2-Adrenergic receptor assay, Raynaud's phenomenon in fibromyalgia, 264
- Agalactosyl IgG, in early synovitis, 1425
- Age
  - IL-1 effects on articular cartilage and (mouse), 607
  - latex fixation test and, 951
  - RA incidence in women and, 1502
  - survival in SSc and, 403
- Allopurinol, sensitivity to, intravenous desensitization for, 1329
- Alprazolam, in primary fibrositis/fibromyalgia syndrome, 552
- American College of Rheumatology (ACR)
  - clinical slide collection, 1991 winners, 1185
  - criteria for classification of osteoarthritis of hip, 505
  - presidential address: medicine—a profession or a trade union, 641
- American Society for Clinical Pharmacology and Therapeutics, Analgesic Guidelines Subcommittee, 931
- Amino acids, sequence of class II MHC genes from MRL mouse, 1411
- Amyloid arthropathy, hemodialysis and, 1061
- Amyloidosis
  - reactive, serum amyloid P restriction fragment length polymorphism, 119
  - reactive systemic, in ankylosing spondylitis, 920
- Analgesics
  - guidelines, 931
  - "Guidelines for the Clinical Evaluation of Analgesic Drugs," 1619
- Androgen(s), replacement therapy, in males with RA, 1
- Anemia, survival in SSc and, 403
- Angiography, cerebral vasculopathy associated with moya moya radiologic phenomenon and anti-Ro/SS-A antibodies, 1052
- Ankylosing spondylitis
  - reactive systemic amyloidosis and, colchicine therapy and, 920
  - soluble IL-2 receptor in, 1622
  - stress protein autoantibodies in, 1133
  - susceptibility in HLA-B27+ patients, HLA-Bw60 and, 247
  - transcutaneous electrical nerve stimulation in, 788
  - tumor necrosis factor region in, restriction fragment length polymorphism of, 486
- Anterior cruciate ligament transection, osteoarthritic changes and (dog), 1560
- Antibiotics, prophylaxis, prosthetic joint infection, 110
- Antibodies. *See also specific antibodies*
  - anticentromere, 68
  - anti-galactosyl ( $\alpha 1 \rightarrow 3$ ) galactose, 375
  - anti-hepatitis C virus, in mixed cryoglobulinemia, 1606
  - anti-La/SS-B, 1052
  - anti-myeloperoxidase, 1069
  - antineuronal, in chronic fatigue syndrome with neurologic abnormalities, 1485
  - antineutrophil cytoplasmic, 1069
  - anti-paternal lymphocytotoxic, recurrent abortion and, 374
  - anti-p24 gag from HIV, 1336
  - antiphospholipid, 1231
  - anti-Ro, 722
  - anti-Ro/SS-A, 888
    - in cerebral vasculopathy associated with moya moya radiologic phenomenon, 1052
  - anti-topoisomerase I, 68
  - arthritogenic, from mice resistant to collagen-induced arthritis, 776
  - monoclonal. *See* Monoclonal antibody(ies)
- Anticentromere antibodies, in Raynaud's disease, 68
- Anticytoplasmic antibodies, in acute familial polymyositis-like syndrome, 744
- Anti-DNA antibodies, in SLE, continuous removal via extracorporeal immunoadsorption system, 1546
- Antigens
  - CD16, 423
  - microbial superantigens, in systemic autoimmune disease, 468
  - PBC 95K, 731
  - recombinant SmB, in ELISA of anti-Sm antibodies, 572
  - Ro/SS-A, 888
    - 60-kd, 722
  - SSc fibroblast surface antigens, 1164
  - Yersinia*, in reactive arthritis, 89
- Antihyperuricemic therapy, clinical and radiographic progression of gout and, 1489
- Anti-IgE, basophil releasability in SSc and, 1289
- Antiinflammatory drugs, nonsteroidal (NSAIDs)
  - clinical outcome and, 127
  - effects on dermal and synovial mast cell-induced vasopermeability (rat), 164
  - inhibition of activated neutrophil collagenase, tenidap sodium vs, 211
  - in vitro effects on osteoarthritic cartilage metalloproteinases, 1332
  - in RA, 120
    - sleep disorders and, 655
  - synovial fluid leukocyte differentials and, 1173
  - relative toxicity, 1353
  - topical, 931



- Anti-Jo-1 antibody**  
in acute familial polymyositis-like syndrome, 744  
seasonal pattern of onset of idiopathic inflammatory myopathy and, 1391
- Anti-La/SS-B antibodies**, in cerebral vasculopathy associated with moya moya radiologic phenomenon, 1052
- Antimalarial drugs**, HIV infection and, 372
- Antineuronal antibodies**, in chronic fatigue syndrome with neurologic abnormalities, 1485
- Antineutrophil cytoplasmic antibodies**, in RA, 1069
- Antinuclear antibodies**  
in connective tissue disease, immunoglobulin Km and Gm phenotypes and, 453  
in primary biliary cirrhosis, 731  
in tight skin mouse model of SSc, 599
- Antiphospholipid antibodies**, in women with recurrent spontaneous abortion, women with successful pregnancies and women who have never been pregnant, 1231
- Anti-PM-Scl antibodies**, in acute familial polymyositis-like syndrome, 744
- Antirheumatic drugs**  
in osteoarthritis, synovial membrane histology and immunopathology and, 153  
placebo vs, 501  
in RA  
analysis of improvement, composite index methodology, 502  
synovial membrane histology and immunopathology and, 153  
synovial mast cells and, 1116
- Anti-Ro/SS-A antibodies**, 888  
in cerebral vasculopathy associated with moya moya radiologic phenomenon, 1052
- Anti-signal recognition particle autoantibodies**, seasonal pattern of onset of idiopathic inflammatory myopathy and, 1391
- Anti-Sm antibodies**, ELISA, use of synthetic C27 peptide and recombinant SmB antigens, 572
- Antithymocyte globulin**, in SSc, 244
- Anti-topoisomerase I antibodies**  
in Raynaud's disease, 68  
in tight skin mouse model of SSc, 599
- Aortic incompetence**, acute, in relapsing polychondritis, 97
- Aqueous suspension**, *Mycobacterium tuberculosis* in, peritoneal injection of, arthritis and (rat), 63
- Arthritis**  
adoptive adjuvant-induced, down-regulation by suppressor factors (rat), 180  
*Chlamydia*, 6  
collagen-induced  
arthritogenic antibody production in mice resistant to, 776  
combination cyclosporin A and methotrexate therapy (rat), 1282  
immune response to (monkey), 616  
monoclonal antibody suppression of (mice), 48  
treatment with monoclonal antibody to  $\alpha/\beta$  T cell antigen receptor (rat), 1039  
cytokine-growth factor interactions in, 697  
erosive, in monoclonal gammopathy, 1600  
HTLV-I-associated, 714
- Arthritis (cont'd)**  
induction by peritoneal injection of aqueous suspensions of mycobacteria (rat), 63  
inflammatory, serum keratan sulfate levels in, 383  
juvenile, systemic-onset, primary pulmonary hypertension in, 1575  
in Lyme disease. *See* Lyme arthritis; Lyme disease metalloproteinases and metalloproteinase inhibitor in synovium, 1085  
*Mycobacterium avium* complex-induced, in AIDS, 1339  
neutrophil inactivation of  $\alpha_2$ -macroglobulin in, 1139  
noninflammatory, serum keratan sulfate levels in, 383  
occupation, income, and education and, 984  
penicillinase-producing strains of *N. gonorrhoeae* and, 245  
reactive. *See* Reactive arthritis  
septic, 84, 1484  
soluble human intestinal peptidoglycan-polysaccharide complexes and (rat), 1611  
synovial fluid enkephalinase in, 1048
- Arthritis Impact Measurement Scales**  
GERI-AIMS scales, 856  
health status in recent-onset RA, 761  
RA and household work performance of women, 669
- Arthrocentesis**, synovial fluid examination after, 118
- Arthropathy**  
amyloid, hemodialysis and, 1061  
autosomal dominant, in French family, 737  
hip, in genetic hemochromatosis, 357
- Arthroplasty**, total joint, in methotrexate-treated RA, post-operative infection and, 146
- Arthroscopy**  
cartilage damage, in osteoarthritis of knee, relation to radiographic evidence of joint space narrowing, 377  
synovectomy, for chronic refractory Lyme arthritis, 1056
- Articular cartilage**  
chondron morphology, in osteoarthritis, 22  
degeneration, in osteoarthritis of knee  
correlation to Kellgren and Lawrence grade and to grade based on joint space narrowing, 1381  
relation to joint space narrowing, 377  
degradation, neutrophil-mediated  
granulocyte-macrophage colony-stimulating factor and, 1452  
IL-8 induction of, 325  
effects of IL-1 (mouse), 606  
IL-1-stimulated erosion, biologic effects of IL-1 receptor antagonist protein on (rabbit), 78  
inorganic pyrophosphate production, transforming growth factor 1 and (pig), 904  
osteoarthritic, in vitro effects of NSAIDs on metalloproteinases, 1332  
osteoarthritic changes, anterior cruciate ligament transection and (dog), 1560  
pannus junction, tumor necrosis factor in, 1125  
phospholipase A<sub>2</sub> in, 1106  
proteoglycan degradation, serum keratan sulfate assay and, 383  
proteoglycan metabolism, IL-1-induced alterations, protein kinase C activation and (bovine), 1006
- Aseptic meningitis**, diclofenac treatment of SLE and, 1340

## Aspirin

- effects on dermal and synovial mast cell-induced vasopermeability (rat), 164
- methotrexate clearance in RA and, 1514
- Atlantoaxial facet joint, involvement in RA, false-positive findings using open-mouth view of odontoid, 125
- Auranofin, for juvenile rheumatoid arthritis, 934

## Autoantibodies

- anti-DNA antibodies in SLE, continuous removal via extracorporeal immunoadsorption system, 1546
- anti-Jo-1, seasonal pattern of onset of idiopathic inflammatory myopathy and, 1391
- anti-signal recognition particle, seasonal pattern of onset of idiopathic inflammatory myopathy and, 1391
- anti-thyroglobulin, epitope specificity in Sjögren's syndrome and Hashimoto's thyroiditis, 1585
- human, structure of, 935
- immunofluorescence patterns produced by autoantibodies to DNA, lamins, and pore complex proteins, 249
- neutrophil, in Felty's syndrome, cyclosporin A in, 253
- to stress proteins, 1133

## Autoimmune disease

- 60-kd Ro/SS-A antigen conformational determinants, 722
- systemic, microbial superantigens in, 468

## Autoimmunity

- anti-thyroglobulin autoantibodies, epitope specificity in Sjögren's syndrome and Hashimoto's thyroiditis, 1585
- cellular, to collagen type I, in Ehlers-Danlos syndrome type VIII, 1466
- gold-induced, role of thiol moiety in (rat), 1594
- in SSc, tight skin mouse model, 599
- systemic, microbial superantigens and, 468

## Azathioprine

- accelerated nodulosis and, 123
- in RA, methotrexate vs, 961

## B

### B cell

- differentiation in SLE, in vitro regulation by IL-6 and soluble CD23, 276
- IgM- and IgG-secreting, in SLE, 1404
- T2 (Chinese herbal remedy) effect on, 1275

### Basic calcium phosphate crystals

- mitogenic response of fibroblasts to, 1021
- synovial fluid purine catabolic enzyme activity and, 1014

### Basic fibroblast growth factor, interactions with IL-1, on articular chondrocytes (rabbit), 314

### Basophil releasability, in SSc, 1289

### Behçet's disease, in child, 791

### Behçet's syndrome, concordance in monozygotic twins, 1071

### Biliary cirrhosis, primary, PBC 95K autoantigen in, 731

### Biliary tract, common hepatic duct cholangiocarcinoma, methotrexate therapy and, 498

### Biopsy

- labial, in Sjögren's syndrome, 1325
- renal, in SLE, prognostic importance, 1268

### Black population, SLE in, strategies for reducing morbidity and mortality, 1187

### *Blastocystis hominis*, reactive arthritis, 251

### Blood urea nitrogen, survival in SSc and, 403

### Body weight, spontaneous osteoarthritis and (guinea pig), 1180

### Bone

- erosion in RA, radiologic progression over 25-year period, 660

### Gla-protein

- corticosteroids and, 1487
- high-dose IV methylprednisolone and, 1487
- subchondral, osteoarthritic changes, anterior cruciate ligament transection and (dog), 1560

### Bone loss, metacarpal, in osteoarthritis of hand, 36

### Bone mass, metacarpal, in osteoarthritis of hand, 36

### Book reviews

### *The Lung in Rheumatic Disease: (Lung Biology in Health and Disease Series, Vol. 45) (Cannon and Zimmerman, eds.), 1208*

### *Osteoporosis: Prevention, Management, Treatment (McIlwain, Bruce, Silverfield, and Burnette), 640*

### *Borrelia burgdorferi. See also Lyme disease*

### T cell proliferation induced by, 393, 707

### Borreliosis, Lyme. See Lyme disease

### Brain, SPECT scan, in cerebral lupus, 1397

## C

### Calcium, mobilization in neutrophils, crystal-induced, 333

### Calcium ionophore A23187, basophil releasability in SSc and, 1289

### Calcium pyrophosphate dihydrate crystals

- articular cartilage production of inorganic pyrophosphate and, 904

### deposition, in metabolic disease, 1297

### neutrophil activation, 333

### synovial fluid purine catabolic enzyme activity and, 1014

### Capillaries, synovial, morphometric image analysis in normal and rheumatoid synovium, 1508

### Cardiac score, prognosis in SSc and, 1371

### Cathepsin B, synovial cell, joint destruction in RA and, 1444

### CD23, soluble, in vitro regulation of SLE B cell differentiation, 276

### CD44 protein, synovial, inflammatory disease activity and, 1434

### Cell proliferation

### endothelial cells, lobenzarit disodium and, 296

### T cells

### *Borrelia burgdorferi*-induced, 393, 707

### CD2-mediated, in SLE, 563

### CD3-mediated, in SLE, 459

### in Reiter's syndrome, *Chlamydia trachomatis* and, 588

### Cellulitis, insufficiency fractures of distal tibia vs, 912

### Central nervous system

### cerebral vasculopathy associated with moya moya radiologic phenomenon and anti-Ro/SS-A antibodies, 1052

### in SLE

### magnetic resonance imaging, 432

### SPECT scan in, 1397

### Cervical spine, septic arthritis of C1-C2 lateral facet joint, 84

### Chemoattractants, in synovial fluid from Lyme disease, 770

## Chinese herbal medicine

- Chufong Toukuwan, corticosteroids and lead in, 1207
- T2, immunosuppression in RA and, 1274

## Chlamydia trachomatis

- reactive arthritis, lymecycline therapy, 6
- synovial T cell response to, in Reiter's syndrome, 588

## Cholangiocarcinoma, common hepatic duct, methotrexate therapy and, 498

## Chondrocalcinosis, 904

## Chondrocytes

- IL-1-activated, biologic effects of IL-1 receptor antagonist protein on (rabbit), 78
- IL-1 and basic fibroblast growth factor interactions (rabbit), 314
- IL-1 and platelet-derived growth factor interactions (rabbit), 697

## Chondrodysplasia, in early-onset primary osteoarthritis, 791

## Chondron, morphologic changes, in osteoarthritic cartilage, 22

## Chronic fatigue syndrome, neurologic abnormalities and, antineuronal antibody levels in, 1485

## Chronic granulomatous disease, X-linked, SLE in, 101

## Chufong Toukuwan, 1207

## Civil War, rheumatic disease among troops, 1197

## Coagulation, extravascular, in RA synovium, 996

## Colchicine

- in gout, 782
- long-term therapy, in pediatric familial Mediterranean fever, 973
- in reactive systemic amyloidosis complicating ankylosing spondylitis, 920

## Collagen

- synthesis, endothelin and, 978

### type I

- cellular autoimmunity to, in Ehlers-Danlos syndrome type VIII, 1466
- in SSC, IL-2 response to, 580
- type II (bovine), arthritis and immune response to (monkey), 616
- type II (calf), arthritis and, treatment with monoclonal antibody to  $\alpha/\beta$  T cell antigen receptor (rat), 1039
- type II (chicken), arthritis and combination cyclosporin A and methotrexate therapy (rat), 1282
- monoclonal antibody suppression of (mice), 48

## Collagenase

- fibroblast secretion, basic calcium phosphate crystal stimulation and, 1021
- gene expression, in RA and osteoarthritic synovium, 1094
- neutrophil, tenidap inhibition of, 211
- in osteoarthritic cartilage, in vitro effects of NSAIDs, 1332
- in RA synovium, 1076, 1085

## Complement system

- Bb cleavage fragment, in synovial fluid in RA, 1531
- C4AQ0 allele, association with primary Sjögren's syndrome in Japanese, 224
- C4d cleavage fragment, in synovial fluid in RA, 1531
- C5 deficiency, resistance to collagen-induced arthritis and (mouse), 776

## Complement system (*cont'd*)

- C1q serum levels in RA, clinical significance of, 187
- gene expression, in RA and osteoarthritic synovium, 1094
- SC5b-9 membrane attack complex, in synovial fluid in RA, 1531

## Computed tomography (CT scan)

- cerebral vasculopathy associated with moya moya radiologic phenomenon and anti-Ro/SS-A antibodies, 1052
- septic arthritis of C1-C2 lateral facet joint and torticollis, 84
- single-photon-emission (SPECT), in cerebral lupus, 1397
- spine, bilateral nervus axillaris palsy after, 1207

## Connective tissue disease

- anti-galactosyl ( $\alpha 1 \rightarrow 3$ ) galactose antibodies in, 375
- association of immunoglobulin Km and Gm phenotypes and antinuclear antibodies, 453
- mixed, stress protein autoantibodies in, 1133

## Coronary artery(ies), vasculitis, in relapsing polychondritis, 97

## Corticosteroids

- in Chinese herbal medicine, 1207
- for De Quervain's tenosynovitis, 793
- local injection, for soft tissue rheumatic disorders, 923
- serum bone Gla-protein and, 1487

## C-reactive protein

- anti-CD4 MAb therapy and, 129, 525
- binding to neutrophils, 1031
- in rheumatology, 1065

## Cryoglobulinemia

- essential, HTLV-I-related proteins and reverse transcriptase activity in, 1313
- mixed, anti-hepatitis C virus antibodies in, 1606

## Culture studies

- biologic effects of IL-1 receptor antagonist protein on IL-1-stimulated cartilage erosion and chondrocyte responsiveness (rabbit), 78
- IL-1-platelet-derived growth factor interactions in articular chondrocytes (rabbit), 697
- regulation of SLE B cell differentiation by IL-6 and soluble CD23, 276
- reverse transcriptase activity in peripheral blood mononuclear cell cultures, in systemic-onset JRA, 126
- T lymphocyte-synovial fibroblast interactions induced by mycobacterial proteins in RA, 679
- transforming growth factor  $\beta 1$  and articular cartilage production of inorganic pyrophosphate (pp<sub>i</sub>), 904

## Cushing's disease, hypophysectomy for, fibromyalgia and, 493

## Cyclophosphamide, in lupus nephritis, renal function and, 945

## Cyclosporin A

- for dermatomyositis, 933
- in Felty's syndrome, neutrophil autoantibodies and, 253
- in kidney transplant recipient, reflex sympathetic dystrophy syndrome of lower limbs in, 625
- methotrexate plus, in collagen arthritis (rat), 1282
- renal eicosanoid excretion in RA and, 481

## Cytokines. *See also specific cytokines*

- $\Delta$ Sc fibroblast binding to T cells and, 1164
- T cell adhesion to synovial fibroblasts and, 1245

## D

- Deflazacort, in chronic inflammatory disorders, prednisone vs, 287
- De Quervain's tenosynovitis, corticosteroid therapy, 793
- Dermatomyositis
  - cyclosporin A therapy, 933
  - HTLV-1 and, in Japanese, 791
  - juvenile, serial MRI in, 1580
  - rectal incontinence in, 1337
  - stress protein autoantibodies in, 1133
- Desensitization, intravenous, in allopurinol sensitivity, 1329
- Diclofenac, in SLE, aseptic meningitis and, 1340
- Digital photoplethysmography, Raynaud's phenomenon in fibromyalgia, 264
- Disability. *See also* Work disability
  - measurement tool, for juvenile rheumatoid arthritis, 873
- Disease flare. *See* Flare
- DNA, binding activity of estrogen receptor, polyamine biosynthesis inhibitor and (mice), 55
- Drugs. *See also specific drugs*
  - second-line drugs in RA
    - combined "effect size," 1342
    - secular trends and comparison of results of clinical trials, 1304
- Dysprosium-165, absorbed dose profile in radiation synovectomy, 1521

## E

- Education, research priorities for arthritis professional education, 234
- Education level, arthritis and, 984
- Ehlers-Danlos syndrome, type VIII, cutaneous vasculitis, resorptive osteolysis, and cellular immunity to type I collagen in, 1466
- Eicosanoids, renal excretion in RA, cyclosporin A and, 481
- Electrical nerve stimulation, transcutaneous, in ankylosing spondylitis, 788
- Electron microscopy, chondron morphology in osteoarthritis cartilage, 22
- Endothelial cells
  - activation, in "uninvolved" scleroderma skin, 1495
  - functional effects of lobenzarit disodium, 296
- Endothelial leukocyte-adherence molecule type 1 (ELAM-1), in "uninvolved" scleroderma skin, 1495
- Endothelin, in SSc, 978
- Endothelin-1, plasma levels, in SSc, 243
- Endothelium, in chronic inflammatory synovitis, 1345
- Enkephalinase, in synovial fluid, 1048
- Enzyme-linked immunosorbent assay (ELISA)
  - antibody profile in Raynaud's disease, 68
  - anti-hepatitis C virus antibodies in mixed cryoglobulinemia, 1606
  - anti-Sm antibodies, use of synthetic C27 peptide and recombinant SmB antigens, 572
  - herpes simplex virus Fc $\gamma$ -binding proteins and rheumatoid factor, 846
  - IgA rheumatoid factor subclass distribution at mucosal and nonmucosal sites, 831

- Enzyme-linked immunosorbent assay (*cont'd*)
  - inhibition, rheumatoid factor cross-reactive idiotype in seropositive RA, 840
  - plasma hyaluronate in osteoarthritis and RA, 799
  - serum keratan sulfate in inflammatory vs noninflammatory arthritides, 383
- Enzyme-linked immunospot assay, IgM- and IgG-secreting B cells in peripheral blood in SLE, 1404
- Eosinophil(s), activation, in SSc, 414
- Eosinophil cationic protein, in SSc, 414
- Epidemiologic studies
  - labor force participation among persons with musculoskeletal conditions (1970-1987), 1361
  - occupation, income, education, and arthritis, 984
  - polymyalgia rheumatica and giant cell arteritis in northern Italy, 351
  - RA in women, 1502
  - shoulder disorders in elderly, community survey, 766
- Erosive arthritis, in monoclonal gammopathy, 1600
- Erythema nodosum, familial, 1177
- Erythrocyte(s), complement receptor type 1, elimination of soluble <sup>125</sup>I-labeled aggregates of human IgG in SLE and, 442
- Erythrocyte sedimentation rate (ESR)
  - anti-CD4 MAb therapy and, 129
  - low, in temporal arteritis, 1571
  - normal, in temporal arteritis, occipital pain and, 217
- Essential cryoglobulinemia, HTLV-I-related proteins and reverse transcriptase activity in, 1313
- Estrogen receptor, DNA binding activity, polyamine biosynthesis inhibitor and (mice), 55
- Ethics, 1204
- European Spondylarthropathy Study Group, criteria for classification of spondylarthropathy, 1218
- Extracorporeal immunoadsorption system, continuous removal of anti-DNA antibodies in SLE, 1546
- Extremities, lower, reflex sympathetic dystrophy syndrome, in renal transplant recipient on cyclosporin A, 625

## F

- Factor XIII, in RA synovium, 996
- Familial erythema nodosum, 1177
- Familial Mediterranean fever, pediatric, long-term colchicine in, 973
- Fc $\gamma$ -binding proteins, herpes simplex virus, rheumatoid factor and, 846
- FDA, "Guidelines for the Clinical Evaluation of Analgesic Drugs," 1619
- FDA Arthritis Advisory Committee
  - analgesics guidelines, 931
  - expanded role for committee members, 1619
  - extracorporeal photochemotherapy in SSc, 931
  - topical NSAIDs, 931
- Fecal incontinence, in dermatomyositis, 1337
- Felty's syndrome
  - HLA-DR-DQ associations in, 1416
  - neutrophil autoantibodies in, cyclosporin A and, 253
- Fibrin D dimer, in RA synovium, 996
- Fibrinogen, in RA synovium, 996
- Fibrinolysis, extravascular, in RA synovium, 996



- Fibroblasts**  
 activation, in "uninvolved" scleroderma skin, 1495  
 dermal  
   growth, endothelin and, 978  
   in SSc, surface antigens on, 1164  
 mitogenic response to basic calcium phosphate crystals, 1021  
 synovial  
   cytokine-stimulated, T cell adhesion to, 1245  
   T cell interactions induced by mycobacterial antigens in RA, 679
- Fibromyalgia**  
 hypophysectomy and, 493  
 parvovirus infection and, 1319  
 primary. *See also* Primary fibromyalgia syndrome  
   relation of clinical features to psychological status, 15  
 Raynaud's phenomenon in, 264  
 tender point examination, pinch strength meter for, 128
- Fibronectin**  
 gene mutation, in SSc in Japanese patients, 490  
 opsonic, in RA synovial fluid, 687
- Fibrositis, ibuprofen and/or alprazolam therapy, 552**
- Flare, in SLE**  
 definition, incidence, and clinical description, 937  
 in pregnancy, 1538
- Formylated tripeptide (f-met peptide), basophil releasability in SSc and, 1289**
- Fourth International Conference on Lyme Borreliosis, 367**
- Fracture(s), insufficiency, 912, 1387**

## G

- Gastritis, mast cell-associated, seronegative JRA and, 106**
- Genes**  
 HLA-Dw16, association with RA in Yakima Indians, 43  
 mutant fibronectin gene, 490  
 serum amyloid P, 119  
 tumor necrosis factor, in ankylosing spondylitis, 486  
 V<sub>H</sub>4 family, 935
- Genetics**  
 autosomal dominant arthropathy in French family, 737  
 clonal diversity of rheumatoid synovial tissue T cells, 537  
 concordance for Behçet's syndrome in monozygotic twins, 1071  
 gene expression in RA and osteoarthritic synovium, 1094  
 HLA and T cell receptor polymorphisms in pauciarticular-onset JRA, 1260  
 immunoglobulin heavy chain constant-region gene polymorphism in SLE, 1553  
 immunoglobulin Km and Gm phenotypes and antinuclear antibodies in connective tissue disease, 453  
 nucleotide sequences of heavy and light chain variable gene segments of a human rheumatoid factor, 343  
 sequence of class II MHC genes from MRL mouse, 1411
- GERI-AIMS scales, 856**
- Geriatric patient**  
 generic and arthritis-specific functional impairment, GERI-AIMS scales, 856  
 occipital pain in, giant cell arteritis and, 217  
 septic arthritis of C1-C2 lateral facet joint and torticollis, 84

- Geriatric patient (cont'd)**  
 shoulder disorders in, community survey, 766
- Giant cell arteritis. *See also* Temporal arteritis in northern Italy, epidemiologic aspects, 351**
- Gla-protein, bone**  
 corticosteroids and, 1487  
 high-dose IV methylprednisolone and, 1487
- Glycosaminoglycan-peptide association complex (GP-C), osteoarthritis therapy (rabbit), 304**
- Gold-198, absorbed dose profile in radiation synovectomy, 1521**
- Gold salts**  
 gold deposition in skin, 1069  
 thiol-containing, autoimmunity and (rat), 1594
- Gout**  
 allopurinol sensitivity in, intravenous desensitization for, 1329  
 antihyperuricemic therapy, clinical and radiographic progression of disease and, 1489  
 colchicine in, 782  
 IL-8 in, 894  
 untreated, persistence of monosodium urate crystals and low-grade inflammation in synovial fluid in, 141
- Granulocyte-macrophage colony-stimulating factor (GM-CSF), neutrophil-mediated cartilage destruction and neutrophil adherence and, 1452**
- Granulomatous disease**  
 chronic, SLE in, 101  
 Wegener's granulomatosis, 220
- Grip strength, in RA, anti-CD4 MAb therapy and, 525**

## H

- Hand**  
 osteoarthritis  
   metacarpal bone loss in, 36  
   radiographic grading scales, 639  
 soft tissue rheumatic disorders, local corticosteroid injection therapy, 923
- Harold C. Simmons Arthritis Research Center, second international conference on HLA-B27-related disorders, 1476**
- Hashimoto's thyroiditis, epitope specificity of anti-thyroglobulin autoantibodies from, 1585**
- Health Assessment Questionnaire, RA and household work performance of women, 669**
- Heart block**  
 complete, in relapsing polychondritis, 97  
 in SLE, pacemaker "exit block" complicating, 121
- Heat-shock proteins, autoantibodies to, 1133**
- Hemochromatosis**  
 genetic, hip arthropathy in, 357  
 synovial fluid inorganic pyrophosphate levels in, 1297
- Hemodialysis, amyloid arthropathy and, 1061**
- Hemoglobin level, survival in SSc and, 403**
- Hepatitis C virus**  
 antibodies to, in mixed cryoglobulinemia, 1606  
 infection, RA and, 1620
- Herpes simplex virus, Fcγ-binding proteins, rheumatoid factor and, 846**



- Hip joint**  
 arthropathy, in genetic hemochromatosis, 357  
 osteoarthritis, classification, 505
- Histamine, release.** *See* Basophil releasability
- Histiocytosis, malignant, in SLE, 1557**
- Histologic studies, hip arthropathy in genetic hemochromatosis, 357**
- Historical perspectives**  
 rheumatic disease among Civil War troops, 1197  
 rheumatoid arthritis: a twentieth century disease in Africa, 248
- HIV infection**  
 type 1  
 antimalarial drugs and, 372  
 rheumatic symptoms in, 257  
 SLE and, 372  
 type 2, rheumatic manifestations, 790
- HLA**  
 class II genes, in pauciarticular-onset JRA, 1260  
 typing, in familial erythema nodosum, 1177
- HLA-B27, spondylarthropathies and, 1476**
- HLA-Bw60, susceptibility of HLA-B27+ patients to ankylosing spondylitis, 246**
- HLA-D, in RA, 193, 933**
- HLA-DPB1\*0301, risk factor for seronegative adult RA, 1310**
- HLA-DQ**  
 in Felty's syndrome, 1416  
 genetic polymorphisms in RA, 1416
- HLA-DR**  
 endothelial cell expression, lobenzarit disodium and, 296  
 in Felty's syndrome, 1416  
 gene expression, in RA and osteoarthritic synovium, 1094  
 genetic polymorphisms in RA, 1416  
 in RA, 193
- HLA-DR4**  
 in polymyalgia rheumatica and giant cell arteritis in northern Italy, 351  
 in RA, severity of disease and, 822
- HLA-DR5, recurrent spontaneous abortion and, 374**
- HLA-Dw15, in Israeli Jews, susceptibility to RA and, 547**
- HLA-Dw16, association with RA in Yakima Indians, 43**
- Holmium-166, absorbed dose profile in radiation synovectomy, 1521**
- Hopkins Lupus Pregnancy Center, frequency of lupus flare in pregnancy, 1538**
- Human immunodeficiency virus (HIV). *See also* HIV infection**  
 antibodies to p24 gag protein, 1336
- Human T lymphotropic virus type I (HTLV-I)**  
 arthritis and, 714  
 essential cryoglobulinemia and, 1313  
 polymyositis/dermatomyositis and, in Japanese, 791
- Hyaluronan. *See* Hyaluronate**
- Hyaluronate**  
 plasma levels, in osteoarthritis and RA, 799, 927  
 serum levels, radiologic progression in early RA and, 815
- Hyaluronate receptor (CD44) molecule, synovial fluid, in RA, 1434**
- Hyperparathyroidism, synovial fluid inorganic pyrophosphate levels in, 1297**
- Hyperplasia, synovial, in mechanically induced osteoarthritis (rabbit), 515**
- Hypersensitivity reaction, in RA, sustained remission following, 789**
- Hypomagnesemia, synovial fluid inorganic pyrophosphate levels in, 1297**
- Hypophysectomy, for Cushing's disease, fibromyalgia and, 493**

## I

- Ibuprofen, in primary fibrositis/fibromyalgia syndrome, 552**
- Idiopathic inflammatory myopathy, seasonal pattern of onset in patients with anti-Jo-1 and anti-signal recognition particle autoantibodies, 1391**
- Immunoblotting**  
 antibody profile in Raynaud's disease, 68  
 60-kd Ro/SS-A antigen conformational determinants, 722
- Immunodiffusion**  
 antibody profile in Raynaud's disease, 68  
 60-kd Ro/SS-A antigen conformational determinants, 722  
 serum-serum precipitin reaction between rodents and humans, 744
- Immunofluorescence techniques**  
 antibody profile in Raynaud's disease, 68  
 antinuclear antibodies in primary biliary cirrhosis, 731  
 bacterial detection in *Yersinia*-induced reactive arthritis, 89  
 immunofluorescence patterns produced by autoantibodies to DNA, lamins, and pore complex proteins, 249  
 $\gamma/\delta$  T cells in rheumatoid synovium, 808
- Immunogenetic studies**  
 HLA and T cell receptor polymorphisms in pauciarticular-onset JRA, 1260  
 polymyalgia rheumatica and giant cell arteritis in northern Italy, 351
- Immunoglobulin(s)**  
 anti-CD4 MAb therapy and, 129  
 heavy chain constant-region gene polymorphism in SLE, 1553
- IgA rheumatoid factor subclass distribution at mucosal and nonmucosal sites, 831**
- IgG**  
 agalactosylated, in early synovitis, 1425  
 intravenous therapy in SLE-associated thrombocytopenia, 787  
 serum level, elimination of soluble  $^{125}\text{I}$ -labeled aggregates of human IgG in SLE and, 442  
 in SLE, 1404  
 IgG2b induction in RA synovial fluid, 1461  
 IgM, in SLE, 1404  
 Km and Gm phenotypes, antinuclear antibodies and, in connective tissue disease, 453  
 response to bovine collagen type II (monkey), 616
- Immunosuppressive agents**  
 in lupus nephritis, preservation of renal function and, 945  
 T2 (Chinese herbal remedy), 1275
- Income level, arthritis and, 984**
- Incontinence, fecal, in dermatomyositis, 1337**
- Indomethacin, effects on dermal and synovial mast cell-induced vasopermeability (rat), 164**

## Infection

- postoperative, in methotrexate-treated RA, 146
- prosthetic joint, antibiotic prophylaxis, 110

## Inflammation

- chronic, endothelium in, 1345
- crystal-induced, IL-8 mediation of, 894
- low-grade, synovial fluid monosodium urate crystals and, in untreated gout, 141
- synovial, in mechanically induced osteoarthritis (rabbit), 515

## Inflammatory disorders

- autoantibodies to stress proteins in, 1133
- CD44 protein in synovial fluid/tissue and, 1434
- chronic, deflazacort vs prednisone in, 287

## In situ hybridization

- gene expression in RA and osteoarthritic synovium, 1094
- metalloproteinases and metalloproteinase inhibitor in arthritic synovium, 1085
- stromelysin and collagenase mRNA in RA synovium, 1076

## Insufficiency fractures

- sacral, 1387
- tibia, misdiagnosis as cellulitis, 912

## Intercellular adhesion molecule type 1 (ICAM-1)

- interaction with CD11a/CD18, T cell adhesion to cytokine-stimulated synovial fibroblasts and, 1245
- SSc fibroblast binding to T cells and, 1164
- in "uninvolved" scleroderma skin, 1495

## Interferon- $\gamma$

- IgG2b induction in RA synovial fluid and, 1461
- in RA, 1621
- stimulation of synovial fibroblasts, T cell adhesion and, 1245

## Interleukin-1 (IL-1)

- articular chondrocyte response to, platelet-derived growth factor and (rabbit), 697
- cartilage erosion and chondrocyte responsiveness and, biologic effects of IL-1 receptor antagonist protein on (rabbit), 78
- cartilage proteoglycan metabolism and, modulation by protein kinase C activation (bovine), 1006
- IgG2b induction in RA synovial fluid and, 1461
- interactions with basic fibroblast growth factor, on articular chondrocytes (rabbit), 314
- in vivo effects on articular cartilage (mouse), 606

## Interleukin-1 $\beta$ (IL-1 $\beta$ ), stimulation of synovial fibroblasts, T cell adhesion and, 1245

## Interleukin-1 receptor antagonist protein, biologic effect on IL-1-stimulated cartilage erosion and chondrocyte responsiveness in vitro (rabbit), 78

## Interleukin-2 (IL-2)

- IgG2b induction in RA synovial fluid and, 1461
- response to human type I collagen stimulation in SSc, 580
- secretion, in primary fibromyalgia syndrome, 866

## Interleukin-2 receptor (IL-2R), soluble, in ankylosing spondylitis, 1622

## Interleukin-3 (IL-3), basophil releasability in SSc and, 1289

## Interleukin-6 (IL-6)

- IgG2b induction in RA synovial fluid and, 1461
- in vitro regulation of SLE B cell differentiation, 276
- serum levels, in systemic JRA, joint involvement and thrombocytosis and, 1158

## Interleukin-8 (IL-8)

- crystal-induced inflammation and, 894
- induction of neutrophil-mediated cartilage degradation, 325

## Intestine, soluble peptidoglycan-polysaccharide complexes, arthritogenicity (rat), 1611

## Isotope studies, elimination of soluble $^{125}$ I-labeled aggregates of human IgG in SLE, 442

## J

### Joint(s). *See also specific joints*

- arthritic,  $\alpha_2$ -macroglobulin in, neutrophil inactivation of, 1139
- destruction, in arthritis, metalloproteinases and, 1073
- replacement. *See* Arthroplasty; Prosthetic joint
- in systemic JRA, serum IL-6 and, 1158

### Joint space narrowing

- in knee osteoarthritis
- relation to arthroscopic evidence of cartilage damage, 377
- relation to Kellgren and Lawrence grade, 1381
- in RA, radiologic progression over 25-year period, 660

### Juvenile arthritis, systemic-onset, primary pulmonary hypertension in, 1575

### Juvenile Arthritis Functional Assessment Report for Children, 873

### Juvenile Arthritis Functional Assessment Report for Parents, 873

### Juvenile dermatomyositis, serial MRI in, 1580

### Juvenile rheumatoid arthritis (JRA)

- auranofin therapy, 934
- disability measurement tool for, 873
- pauciarticular-onset, HLA and T cell receptor polymorphism in, 1260
- pregnancy and, 881
- seronegative, mast cell-associated gastritis and, 106
- systemic-onset
- IL-6, joint involvement, and thrombocytosis in, 1158
- reverse transcriptase activity in peripheral blood mononuclear cell cultures, 126

## K

### Kellgren and Lawrence scale, severity of knee osteoarthritis, relation to grade based on joint space narrowing, 1381

### Keratan sulfate

- serum levels
- inflammatory vs noninflammatory arthritides and, 383
- in knee osteoarthritis, 1254
- synovial fluid, in knee osteoarthritis, 1254

### Ketoprofen, effects on dermal and synovial mast cell-induced vasopermeability (rat), 164

### Ketotifen, in early diffuse SSc, 362

### Kidney biopsy, in SLE, prognostic importance, 1268

### Kidney function, in lupus nephritis, cyclophosphamide therapy and, 945

### Kidney transplantation, cyclosporin A in, reflex sympathetic dystrophy syndrome of lower limbs and, 625

**Knee joint**  
 meniscal ossification, 638  
 osteoarthritis  
   anterior cruciate ligament transection and (dog), 1560  
   body weight and (guinea pig), 1180  
   radiographic grading, 1381  
   relation between arthroscopic evidence of cartilage damage and radiographic evidence of joint space narrowing, 377  
   serum and synovial fluid levels of keratan sulfate, 1254

## L

Labial biopsy, in Sjögren's syndrome, 1325  
 Latex fixation test, sensitivity and specificity, 951  
 Lead, in Chinese herbal medicine, 1207  
**Leukocyte(s)**  
   differential count, in RA, drug therapy and, 1173  
   *Yersinia* in, 89  
**Leukocyte function-associated antigen 3 (LFA-3)**, T cell adhesion to cytokine-stimulated synovial fibroblasts and, 1245  
**Leukotriene B<sub>4</sub>**, synovial fluid, tenidap sodium and, 204  
**Lobenzarit disodium (CCA)**, endothelial cell effects, 296  
**Lupus erythematosus**, D-penicillamine-induced, 1343  
**Lupus nephritis**, cyclophosphamide therapy, renal function and, 945  
**Lyme arthritis**  
   chronic refractory, arthroscopic synovectomy for, 1056  
   T cell responses to *Borrelia burgdorferi* polypeptide fragments in, 707  
**Lymecycline**, for reactive arthritis, 6  
**Lyme disease**  
   stress protein autoantibodies in, 1133  
   summary of Fourth International Conference, 367  
   synovial fluid neutrophil chemotactic factors, 770  
   T cell proliferation in, 393  
**Lymphocyte(s)**. *See also* B cell; T cell  
   labial salivary gland infiltration, in Sjögren's syndrome, 1070  
   large granular, regression of large subpopulation of, in RA, 246

## M

**$\alpha_2$ -Macroglobulin**, in arthritic joints, neutrophil inactivation of, 1139  
**Macrophages**. *See also* Monocyte(s)  
   in RA synovium, 996  
**Magnetic resonance imaging (MRI)**  
   cerebral vasculopathy associated with moya moya radiologic phenomenon and anti-Ro/SS-A antibodies, 1052  
   CNS lesions in SLE, 432  
   septic arthritis of C1-C2 lateral facet joint and torticollis, 84  
   serial, in juvenile dermatomyositis, 1580  
**Major histocompatibility complex**. *See also* HLA  
   class II molecules, sequence of gene from MRL mouse, 1411  
**Malignant histiocytosis**, in SLE, 1557

**Mast cell(s)**  
   dermal, effects of NSAIDs (rat), 164  
   synovial  
     effects of NSAIDs (rat), 164  
     in RA and osteoarthritis, 1116  
**Mast cell disease**, gastritis, JRA and, 106  
**Matrix metalloproteinases**  
   in arthritic synovium, 1076, 1085  
   glycosaminoglycan-peptide association complex and (rabbit), 304  
   joint destruction in arthritis and, 1073  
   in osteoarthritic cartilage, in vitro effects of NSAIDs, 1332  
   production by IL-1-activated chondrocytes  
     biologic effects of IL-1 receptor antagonist protein on (rabbit), 78  
     platelet-derived growth factor and (rabbit), 697  
**Medicine**, a profession or a trade union, 641  
**Medicolegal issues**, managing toxicopathic rheumatic disease in current legal climate, 634  
**Memory cells**, in chronic inflammation, 1345  
**Meningitis**, aseptic, diclofenac treatment of SLE and, 1340  
**Metalloproteinases**. *See* Matrix metalloproteinases  
**Methotrexate**  
   cyclosporin A plus, in collagen arthritis (rat), 1282  
   disposition in RA, aspirin and, 1514  
   low-dose therapy, cholangiocarcinoma of common hepatic duct and, 498  
   in RA  
     azathioprine vs, 961  
     postoperative infection and, 146  
     radiologic progression of disease and, 1236  
     synovial membrane histology and immunopathology and, 153  
**8-Methoxypsoralen**, photochemotherapy in RA, 646  
**Methylprednisolone**, high-dose intravenous therapy, serum bone Gla-protein and, 1487  
**Methylprednisolone acetate**, for De Quervain's tenosynovitis, 793  
**Milwaukee shoulder syndrome**, synovial fluid 5'-nucleotidase activity, 1014  
**Minnesota Multiphasic Personality Inventory (MMPI)**, in primary fibromyalgia syndrome, 15  
**Mixed cryoglobulinemia**, anti-hepatitis C virus antibodies in, 1606  
**Monoclonal antibody(ies)**  
   anti-CD4 MAb treatment of RA  
     MAb 16H5, 129  
     MAb M-T151, 525  
   suppression of chicken type II collagen-induced arthritis (mice), 48  
   against  $\alpha/\beta$  T cell antigen receptor, treatment of collagen arthritis (rat), 1039  
**Monoclonal gammopathy**, erosive arthritis in, 1600  
**Monocyte(s)**. *See also* Macrophages  
   proteolytic activity, in RA, 1430  
   T2 (Chinese herbal remedy) effect on, 1275  
**Monosodium urate crystals**  
   inflammation and, IL-8 mediation of, 894  
   neutrophil activation, 333  
   synovial fluid, low-grade inflammation and, in untreated gout, 141

Morphometric image analysis, microvasculature in normal and rheumatoid synovium, 1508  
 Moya moya radiologic phenomenon, in cerebral vasculopathy with associated anti-Ro/SS-A and anti-La/SS-B antibodies, 1052  
 Musculoskeletal disorders, labor force participation among persons with (1970-1987), 1361  
 Myalgia, HIV type 2 infection and, 790  
*Mycobacterium avium* complex, chronic arthritis and, in AIDS, 1339  
*Mycobacterium tuberculosis*  
   acetone-precipitable fraction (AP-MT), T cell-synovial fibroblast interactions and, in RA, 679  
   in aqueous suspension, peritoneal injection of, arthritis and (rat), 63  
 Myeloperoxidase, antibodies to, in RA, 1069  
 Myocardium, in SSc, nifedipine and, 198

## N

Natural killer (NK) cells, interaction with rheumatoid factor complexes, in RA, 423  
*Neisseria gonorrhoeae*, penicillinase-producing strains, arthritis and, 245  
 Nervus axillaris palsy, bilateral, CT scan of spine and, 1207  
 Neurologic abnormalities, in chronic fatigue syndrome, antineuronal antibody levels in, 1485  
 Neutrophil(s)  
   activation, crystal-induced, 333  
   cartilage degradation  
     granulocyte-macrophage colony-stimulating factor and, 1452  
     IL-8 and, 325  
   chemotactic factors, in synovial fluid of Lyme disease patients, 770  
   C-reactive protein binding to, 1031  
   inactivation of  $\alpha_2$ -macroglobulin in arthritic joints, 1139  
   migration, in arthritis, 270  
   respiratory burst activity, C-reactive protein binding and, 1031  
 Neutrophil collagenase, activated, tenidap inhibition of, 211  
 Nielsen test, Raynaud's phenomenon in fibromyalgia, 264  
 Nifedipine, effect on myocardial perfusion and metabolism in SSc, 198  
 Nodulosis, accelerated, azathioprine therapy and, 123  
 Nucleoside triphosphate pyrophosphohydrolase, synovial fluid, calcium crystal deposition and, 1014  
 5'-Nucleotidase, synovial fluid, 1014

## O

Obesity, spontaneous osteoarthritis and (guinea pig), 1180  
 Occipital neuralgia, temporal arteritis with normal ESR and, 217  
 Occupation, arthritis and, 984  
 Occupational risks  
   managing toxicopathic rheumatic disease in current legal climate, 634  
   SSc and cutaneous solvent exposure, 631  
 Odontoid process, open-mouth view, atlantoaxial facet joint involvement in RA, 125

Opsonic fibronectin, in RA synovial fluid, 687  
 Oral contraceptives, RA and, 372, 498, 1502  
 Organic solvents, cutaneous exposure to, SSc and, 631  
 Ossification, human menisci, 638  
 Osteoarthritis  
   anterior cruciate ligament transection and (dog), 1560  
   antirheumatic drug therapy, synovial membrane histology and immunopathology and, 153  
   chondron morphology in, 22  
   early-onset, chondrodysplasia and, 791  
   extra-vascular fibrin formation/dissolution in synovium, 996  
   gene expression in synovium, 1094  
   glycosaminoglycan-peptide association complex therapy (rabbit), 304  
   hand  
     metacarpal bone loss in, 36  
     radiographic grading scales, 639  
   hip, classification, 505  
   joint destruction in, metalloproteinases and, 1073  
   knee  
     body weight and (guinea pig), 1180  
     radiographic grading, 1381  
     relation between arthroscopic evidence of cartilage damage and radiographic evidence of joint space narrowing, 377  
     serum and synovial fluid levels of keratan sulfate, 1254  
   leukocyte migration in, 270  
   localization of tumor necrosis factor in synovial tissues, 1125  
   mechanically induced, synovial membrane changes (rabbit), 515  
   metalloproteinases and metalloproteinase inhibitor in synovium, 1085  
   plasma hyaluronate in, 799, 927  
   serum keratan sulfate levels in, 383, 1254  
   socioeconomic status and, 984  
   synovial fluid nucleoside triphosphate pyrophosphohydrolase activity, calcium crystal deposition and, 1014  
   synovial fluid 5'-nucleotidase activity, 1014  
   synovial mast cells in, 1116  
 Osteoarthritis, trapeziometacarpal, in painting by Diego Velazquez, 127  
 Osteolysis, resorptive, in Ehlers-Danlos syndrome type VIII, 1466

## P

Paget's pseudosarcoma, 241  
 Pain, occipital, temporal arteritis with normal ESR and, 217  
 Pannus  
   formation, T cell-synovial fibroblast interactions and, 679  
   tumor necrosis factor in, 1125  
 Paraproteinemia, erosive arthritis in, 1600  
 Parvovirus infection, fibromyalgia and, 1319  
 Pediatric patient  
   Behçet's disease in, 791  
   familial Mediterranean fever, long-term colchicine in, 973  
   seronegative JRA and mast cell-associated gastritis, 106  
   SLE in chronic granulomatous disease, 101



- Pediatric patient (*cont'd*)  
 systemic-onset juvenile arthritis, primary pulmonary hypertension in, 1575
- D-Penicillamine, lupus erythematosus and, 1343
- Peptidoglycan-polysaccharide complexes, intestinal, arthritogenicity (rat), 1611
- Pericardial tamponade, pulmonary hypertension secondary to generalized venulitis and, 228
- Pharmacokinetics, tenoxicam, 751
- Phenotypes, immunoglobulin Km and Gm phenotypes, antinuclear antibodies and, in connective tissue disease, 453
- Phospholipase A<sub>2</sub>, in articular cartilage, 1106
- Phosphorus-32, absorbed dose profile in radiation synovectomy, 1521
- Photochemotherapy  
 in RA, 646  
 in SSc, 931
- Pinch strength meter, in tender point examination, 128
- β<sub>2</sub>-Plasmin inhibitor, in RA synovium, 996
- Platelet(s)  
 β<sub>2</sub>-adrenergic receptors, Raynaud's phenomenon in fibromyalgia and, 264  
 count, in systemic JRA, serum IL-6 and, 1158  
 Ro/SS-A antigen in, 888
- Platelet-derived growth factor  
 IgG2b induction in RA synovial fluid and, 1461  
 potentiation of articular chondrocyte response to IL-1 (rabbit), 697
- Pleural effusion, massive, in SLE, tetracycline pleurodesis for, 1483
- Polymine, uterine production, DNA binding activity of estrogen receptor and (mice), 55
- Polyarthritis, spontaneous degenerative, in male New Zealand black/KN mice, 171
- Polymerase chain reaction  
 bacterial detection in *Yersinia*-induced reactive arthritis, 89  
 sequence of class II MHC genes from MRL mouse, 1411
- Polymorphonuclear cells (PMNs), degranulation, in RA, tenidap sodium and, 204
- Polymyalgia rheumatica  
 deflazacort vs prednisone in, 287  
 in northern Italy, epidemiologic aspects, 351
- Polymyositis  
 HTLV-1 and, in Japanese, 791  
 stress protein autoantibodies in, 1133
- Polymyositis-like syndrome, serum-serum precipitin reaction between rodents and humans, 744
- Positron emission tomography (PET), nifedipine and myocardial perfusion in SSc, 198
- Prednisone  
 in chronic inflammatory disorders, deflazacort vs, 287  
 low-dose therapy in RA, placebo vs, 501  
 in lupus nephritis, cyclophosphamide vs, 945  
 synovial membrane histology and immunopathology and, 153
- Pregnancy  
 juvenile rheumatoid arthritis and, 881  
 SLE flare in, frequency of, 1538  
 successful, antiphospholipid antibodies in, 1231
- Primary fibromyalgia syndrome  
 ibuprofen and/or alprazolam therapy, 552  
 IL-2 secretion in, 866  
 psychological status in, clinical features and, 15  
 serum keratan sulfate levels in, 383
- Primary pulmonary hypertension, in systemic-onset juvenile arthritis, 1575
- Procollagen-1, in "uninvolved" scleroderma skin, 1495
- Prostaglandin E<sub>2</sub>  
 production by IL-1-activated chondrocytes  
 biologic effects of IL-1 receptor antagonist protein on (rabbit), 78  
 platelet-derived growth factor and (rabbit), 697  
 protein kinase C activation and (bovine), 1006  
 synovial fluid, tenidap sodium and, 204
- Prosthetic joint, infection, antibiotic prophylaxis, 110
- Protein kinase C, IL-1-induced alterations in cartilage proteoglycan metabolism and (bovine), 1006
- Proteoglycanase, in osteoarthritic cartilage, in vitro effects of NSAIDs, 1332
- Proteoglycans, metabolism in articular cartilage, IL-1-induced alterations, protein kinase C activation and (bovine), 1006
- Pseudogout, 904
- Pseudo-Grisel's syndrome, 84
- Pseudosarcoma, Paget's, 241
- Psychological status, in primary fibromyalgia, clinical features and, 15
- Pulmonary hypertension  
 primary, in systemic-onset juvenile arthritis, 1575  
 primary generalized venulitis and, 228
- Pyrophosphate, inorganic  
 articular cartilage production, transforming growth factor β1 and (pig), 904  
 in metabolic disease, calcium pyrophosphate dihydrate crystal deposition and, 1297

## R

- Radiation synovectomy, absorbed dose profiles for radionuclides, 1521
- Radiography  
 amyloid arthropathy accompanying hemodialysis, 1061  
 antihyperuricemic therapy and progression of gout, 1489  
 grading of knee osteoarthritis, relation of Kellgren and Lawrence grade to grade based on joint space narrowing, 1381  
 grading scales for osteoarthritis of hand, 639  
 hip arthropathy in genetic hemochromatosis, 357  
 joint space narrowing, in osteoarthritis of knee, relation to arthroscopic evidence of cartilage damage, 377  
 moya moya radiologic phenomenon, in cerebral vasculopathy with associated anti-Ro/SS-A and anti-La/SS-B antibodies, 1052  
 progression of RA  
 methotrexate therapy and, 1236  
 25-year followup, 660  
 sacral insufficiency fracture, 1387
- Radionuclides, for radiation synovectomy, absorbed dose profiles, 1521



- Raynaud's disease, anticentromere and anti-topoisomerase I antibodies in, prognostic significance, 68
- Raynaud's phenomenon  
 endothelin and, 978  
 in fibromyalgia, 264  
 plasma tissue-type plasminogen activator and von Willebrand factor in, 255
- Reactive arthritis  
*Blastocystis hominis* and, 251  
 lymecycline therapy, 6  
*Yersinia*-triggered  
   bacterial detection via polymerase chain reaction, 89  
   isolation of *Yersinia*-specific T cell clones from synovial fluid and synovial membrane in, 1151
- Reactive systemic amyloidosis, in ankylosing spondylitis, colchicine therapy and, 920
- Recombinant SmB antigens, in ELISA of anti-Sm antibodies, 572
- Reflex sympathetic dystrophy syndrome, lower limbs, in renal transplant recipient on cyclosporin A, 625
- Reiter's syndrome  
 stress protein autoantibodies in, 1133  
 synovial T cell response to *Chlamydia trachomatis* in, 588
- Relapsing polychondritis, complete heart block and acute aortic incompetence in, 97
- Research, priorities for arthritis professional education, 234
- Restriction fragment length polymorphism  
 HLA and T cell receptor polymorphisms in pauciarticular-onset JRA, 1260  
 HLA-DR, HLA-DQ, and T cell receptor  $\beta$  chain gene in RA, 1416  
 immunoglobulin heavy chain constant-region gene in SLE, 1553  
 serum amyloid P, reactive amyloidosis and, 119  
 tumor necrosis factor region in ankylosing spondylitis, 486
- Retroviral proteins  
 antibodies to, in essential cryoglobulinemia, 1313  
 gag proteins, antibodies to, in SSc, 1336
- Reverse transcriptase activity  
 in essential cryoglobulinemia, 1313  
 in peripheral blood mononuclear cell cultures, in systemic-onset JRA, 126
- Rhenium-186, absorbed dose profile in radiation synovectomy, 1521
- Rheumatic disease  
 autoantibodies to stress proteins in, 1133  
 in Civil War troops, 1197  
 classification criteria revisited, 1228  
 in HIV infection, 257  
 HIV type 2 infection and, 790  
 managing toxicopathic rheumatic disease in current legal climate, 634  
 nonarticular, local corticosteroid injection therapy, 923  
 NSAIDs in, clinical outcome and, 127  
 serum keratan sulfate levels in, 383  
 synovial fluid enkephalinase in, 1048
- Rheumatoid arthritis (RA)  
 anti-CD4 monoclonal antibody therapy  
   MAb 16H5, 129  
   MAb M-T151, 525
- Rheumatoid arthritis (*cont'd*)  
 antineutrophil cytoplasmic antibodies and anti-myeloperoxidase antibodies in, 1069  
 antiquity of, twentieth century disease in Africa, 248  
 antirheumatic drug therapy  
   analysis of improvement, composite index methodology, 502  
   placebo vs, 501  
   synovial membrane histology and immunopathology and, 153  
 atlantoaxial facet joint involvement, false-positive findings using open-mouth view of odontoid, 125  
 azathioprine therapy, accelerated nodulosis and, 123  
 Chinese herbal medicine, dangers of Chuifong Toukuwan, 1207  
 clinical improvement in, criteria for, 499  
 clinical trials in, design, analysis and reporting, 124  
 clinical trials of second-line drugs, secular trends and comparison of results, 1304  
 C-reactive protein in, 1065  
 deflazacort vs prednisone in, 287  
 diversity of synovial tissue T cells, 537  
 dominant DR1/Dw4/Dw14 gene sequence motif in, 1416  
 eicosanoid excretion in, cyclosporin A and, 481  
 extracorporeal photochemotherapy, 646  
 extracellular fibrin formation/dissolution in synovium, 996  
 gene expression in synovium, 1094  
 hepatitis C virus infection and, 1620  
 HLA-D alleles in, 933  
 HLA-D region antigens in, 193  
 HLA-DR4 in, severity of disease and, 822  
 household work performance of women and, 669  
 hyaluronate receptor (CD44) molecule in synovial fluid from, 1434  
 IgA rheumatoid factor distribution at mucosal and nonmucosal sites, 831  
 insufficiency fractures of tibia in, misdiagnosis as cellulitis, 912  
 interferon- $\gamma$  vs placebo in, 1621  
 joint destruction in  
   cathepsin B in synovial cells and, 1444  
   cytokine-growth factor interactions and, 697  
   metalloproteinases and, 1073  
   radiologic progression over 25-year period, 660  
   serum hyaluronate levels and, 815  
   stromelysin and collagenase and, 1076  
 juvenile. *See* Juvenile rheumatoid arthritis  
 latex fixation test revisited, 951  
 leukocyte migration in, 270  
 localization of tumor necrosis factor in synovial tissues and at cartilage-pannus junction, 1125  
 in males, androgen replacement therapy, 1  
 metalloproteinases and metalloproteinase inhibitor in synovium, 1085  
 methotrexate therapy  
   aspirin therapy plus, 1514  
   azathioprine vs, 961  
   radiologic progression of disease and, 1236  
 microvasculature of synovium in, morphometric image analysis, 1508

### Rheumatoid arthritis (*cont'd*)

- monocyte-associated proteolytic activity in, 1430
  - mycobacteria-reactive T cell-synovial fibroblast interactions in, 679
  - natural killer cells in, 423
  - NSAIDs in, 120
  - oral contraceptive use and, 372, 498, 1502
  - penicillamine therapy, lupus erythematosus and, 1343
  - plasma hyaluronate in, 799, 927
  - prednisone therapy, placebo treatment, 501
  - radiation synovectomy in, 1521
  - radiologic progression over 25-year period, 660
  - recent-onset, clinical and health status of patient, 761
  - regression of expanded subpopulation of large granular lymphocytes in, 246
  - second-line drugs in
    - combined "effect size," 1342
    - secular trends and comparison of results of clinical trials, 1304
  - seronegative, HLA-DPB1\*0301 and, 1310
  - seropositive, rheumatoid factor cross-reactive idiotype in, 840
  - serum C1q levels in, clinical significance, 187
  - serum keratan sulfate levels in, 383
  - sleep disorders in, tenoxicam therapy and, 655
  - socioeconomic status and, 984
  - stress protein autoantibodies in, 1133
  - stromelysin and collagenase in synovium, 1076
  - susceptibility to, in Israeli Jews, HLA-Dw15 allele and, 547
  - sustained remission after hypersensitivity reaction, 789
  - synovial fluid complement SC5b-9 and fragments Bb and C4d levels in, 1531
  - synovial fluid IgG2b-inducing activity in, 1461
  - synovial fluid leukocyte differentials in, drug therapy and, 1173
  - synovial fluid 5'-nucleotidase activity, 1014
  - synovial fluid opsonic fibronectin, 687
  - synovial mast cells in, 1116
  - synovial membrane  $\gamma/\delta$  T cell population in, 808
  - T cell receptor chain genetic polymorphisms in, 1416
  - T2 (Chinese herbal remedy) in, 1275
  - tenidap sodium in, 204
  - total joint arthroplasty in, methotrexate and postoperative infection in, 146
  - vitamin E in, 1205
  - in women, incidence rates, 1502
  - in Yakima Indians, HLA-Dw16 in, 43
- ### Rheumatoid factor
- anti-CD4 MAb therapy and, 129
  - herpes simplex virus Fc $\gamma$ -binding proteins and, 846
  - IgA subclass distribution at mucosal and nonmucosal sites, 831
  - latex fixation test revisited, 951
  - nucleotide sequences of heavy and light chain variable gene segments, 343
- ### Rheumatoid factor complex, interaction with NK cells, 423
- ### Rheumatoid factor cross-reactive idiotype (RF-CRI), serum levels, in seropositive RA, 840

### Rheumatology

- adequacy of manpower, health care needs and physician supply, 1209
- C-reactive protein in, 1065
- role in 1990s, 496
- Ritchie articular index, anti-CD4 MAb therapy and, 129, 525
- RNA, Ro/SS-A-binding, 888
- Ro/SS-A antigen
  - 60-kd, conformational determinants, 722
  - in platelets, 888
- Rumalon. *See* Glycosaminoglycan-peptide association complex

## S

- ### Sacrum, insufficiency fracture, 1387
- ### Saliva, IgA rheumatoid factor level in, 831
- ### Salivary gland, labial, lymphocytic infiltration, in Sjögren's syndrome, 1070
- ### Scintigraphy, leukocyte migration in arthritis, 270
- ### Scleroderma. *See* Systemic sclerosis
- ### Septic arthritis
- Achromobacter xylosoxidans*, in SLE, 1484
  - C1-C2 lateral facet joint, torticollis and, 84
- ### Shoulder disorders, in elderly population, 766
- ### Sjögren's syndrome
- epitope specificity of anti-thyroglobulin autoantibodies from, 1585
  - labial salivary gland lymphocytic infiltration in, 1070
  - negative labial biopsy in, 1325
  - primary, in Japanese, C4AQ0 allele and, 224
  - stress protein autoantibodies in, 1133
  - summary of third international symposium, 1617
- ### Skin
- gold deposition in, 1069
  - mast cell-induced vasopermeability, NSAIDs and (rat), 164
- ### Sleep disorders, in RA, tenoxicam therapy and, 655
- ### Socioeconomic status, arthritis and, 984
- ### Soft tissue, rheumatic disorders, local corticosteroid injection therapy, 923
- ### SPECT. *See* Computed tomography, single-photon-emission
- ### Spondylarthropathies
- classification, 1228
  - European Spondylarthropathy Study Group criteria, 1218
  - HLA-B27-associated, 1476
- ### Steroid therapy. *See also* Corticosteroids
- low ESR in temporal arteritis and, 1571
- ### Stress proteins, autoantibodies to, 1133
- ### Stromelysin, in RA synovium, 1076, 1085
- ### Superoxide anions, production in neutrophils
- C-reactive protein binding and, 1031
  - crystal-induced, 333
- ### Suppressor factors, in adoptive adjuvant-induced arthritis (rat), 180
- ### Survival tree analysis, predictors of survival in SSc, 403
- ### Swelling, facial, pulmonary hypertension secondary to generalized venulitis and, 228

## Synovectomy

- arthroscopic, for chronic refractory Lyme arthritis, 1056
- radiation, absorbed dose profiles for radionuclides, 1521

## Synovial fluid

- complement SC5b-9 and fragments Bb and C4d levels, in RA, 1531
- enkephalinase in, 1048
- examination, after arthrocentesis, 118
- hyaluronate receptor (CD44) molecule in, in RA, 1434
- IgA rheumatoid factor level in, 831
- IgG2b-inducing activity, in RA, 1461
- isolation of *Yersinia*-specific T cell clones, in reactive arthritis, 1151
- keratan sulfate levels, in knee osteoarthritis, 1254
- leukocyte differential, in RA, drug therapy and, 1173
- neutrophil chemotactic factors, in Lyme disease, 770
- 5'-nucleotidase activity, 1014
- opsonic fibronectin in, in RA, 687
- persistence of monosodium urate crystals and low-grade inflammation in, in untreated gout, 141
- T cell response to *Chlamydia trachomatis* in Reiter's syndrome, 588
- tenoxicam pharmacokinetics, 751
- Yersinia* in, 89

## Synovial membrane

- histology, antirheumatic drug therapy and, 153
- immunopathology, antirheumatic drug therapy and, 153

## Synovitis

- chronic inflammatory, endothelium in, 1345
- early, agalactosyl IgG in, 1425
- inflammatory
  - gene expression in, 1094
  - hyaluronate receptor (CD44) molecule in, 1434

## Synovium

- arthritic
    - extravascular fibrin formation/dissolution in, 996
    - gene expression in, 1094
    - isolation of *Yersinia*-specific T cell clones from, 1151
    - metalloproteinases and metalloproteinase inhibitor in, 1085
    - tumor necrosis factor  $\alpha$  in, 1125
  - cathepsin B in, joint destruction in RA and, 1444
  - hyaluronate receptor (CD44) molecule in, in RA, 1434
  - inflammation, in mechanically induced osteoarthritis (rabbit), 515
  - mast cell-induced vasopermeability, NSAIDs and (rat), 164
  - mast cells, in RA and osteoarthritis, 1116
  - microvasculature, morphometric image analysis in normal and rheumatoid synovium, 1508
  - osteoarthritic changes, anterior cruciate ligament transection and (dog), 1560
  - stromelysin and collagenase in, in RA, 1076
  - T cell diversity in RA, T cell receptor analysis, 537
  - $\gamma\delta$  T cell population, in RA, 808
- Synthetic C27 peptide, in ELISA of anti-Sm antibodies, 572
- Systemic lupus erythematosus (SLE)
  - Achromobacter xylosoxidans* septic arthritis in, 1484
  - AIDS and, 372

## Systemic lupus erythematosus (cont'd)

- anti-DNA antibodies in, continuous removal via extracorporeal immunoabsorption system, 1546
  - anti-Sm antibodies, ELISA, 572
  - B cell differentiation, in vitro regulation by IL-6 and soluble CD23, 276
  - in black population, strategies for reducing morbidity and mortality, 1187
  - CD2 pathway T cell activation in, 561
  - in chronic granulomatous disease, 101
  - CNS involvement
    - magnetic resonance imaging, 432
    - SPECT evaluation in, 1397
  - C-reactive protein in, 1065
  - diclofenac therapy, aseptic meningitis and, 1340
  - discordance for, in monozygotic twins concordant for myasthenia gravis, 916
  - DNA binding activity of estrogen receptor in (mice), 55
  - flare
    - definition, incidence, and clinical description, 937
    - in pregnancy, frequency of, 1538
  - genetic susceptibility, environmental factors and, 916
  - glomerulonephritis and, cyclophosphamide therapy and renal function in, 945
  - heart block in, pacemaker "exit block" complicating, 121
  - IgM- and IgG-secreting B cells in peripheral blood, 1404
  - immune complex clearance in, serum IgG and erythrocyte complement receptor 1 and, 442
  - immunoglobulin heavy chain constant-region gene polymorphism in, 1553
  - kidney biopsy in, prognostic importance, 1268
  - malignant histiocytosis in, 1557
  - in patient with 47,XXX karyotype, 371
  - pleural effusion in, tetracycline pleurodesis for, 1483
  - stress protein autoantibodies in, 1133
  - survival analysis according to renal biopsy results, 1268
  - T cell proliferation in, CD3-mediated, 459
  - thrombocytopenia and, intravenous IgG for, 787
- Systemic sclerosis (SSc)
  - antibody to retroviral gag proteins in, 1336
  - anti-galactosyl ( $\alpha$ 1 $\rightarrow$ 3) galactose antibodies in, 375
  - antithymocyte globulin therapy, 244
  - basophil releasability in, 1289
  - cardiac involvement and prognosis, cardiac scoring technique, 1371
  - cutaneous solvent exposure and, 631
  - dermal fibroblast surface antigens, 1164
  - endothelial and fibroblastic activation in "uninvolved" skin, 1495
  - endothelin in, 978
  - eosinophil activation in, 414
  - extracorporeal photochemotherapy, 931
  - IL-2 response to human type I collagen stimulation in, 580
  - ketotifen vs placebo in, 362
  - mutant fibronectin gene in, 490
  - myocardial perfusion and metabolism in, nifedipine and, 198
  - plasma endothelin-1 in, 243
  - stress protein autoantibodies in, 1133
  - survival in, predictors of, 403
  - tight skin mouse model, autoimmunity in, 599

## T

### T cell

#### activation

- CD3-mediated, in SLE, 459
- CD2 pathway, in SLE, 561
- in primary fibromyalgia syndrome, 866

#### adhesion

- to cytokine-stimulated synovial fibroblasts, 1245
- to SSc dermal fibroblasts, 1164

#### $\alpha/\beta$ -positive, in collagen-induced arthritis (rat), 1039

- endothelial cell adhesion, lobenzarit disodium and, 296

#### $\gamma/\delta$ T cells in rheumatoid synovium, 808

- memory cells in chronic inflammation, 1345

#### proliferation

- Borrelia burgdorferi*-induced, in Lyme disease, 393

- CD3-mediated, in SLE, 459

- in Reiter's syndrome, *Chlamydia trachomatis* and, 588

- response to *Borrelia burgdorferi* polypeptide fractions, in Lyme arthritis, 707

- response to bovine collagen type II (monkey), 616

- synovial, response to *Chlamydia trachomatis* in Reiter's syndrome, 588

- synovial fibroblast interactions induced by mycobacterial antigens in RA, 679

- T2 (Chinese herbal remedy) effect on, 1275

- Yersinia*-specific T cell clones in synovial membrane and synovial fluid of patient with reactive arthritis, 1151

### T cell receptor analysis

- $\beta$  chain genetic polymorphisms, in RA, 1416

- diversity of synovial tissue T cells in RA, 537

- polymorphisms in pauciarticular-onset JRA, 1260

- T2 (Chinese herbal remedy), immunosuppression in RA and, 1274

### Tamponade. See Pericardial tamponade

### Temporal arteritis

- low ESR in, 1571

- normal ESR in, occipital pain and, 217

- Wegener's granulomatosis and, 220

### Tender point examination, pinch strength meter for, 128

### Tendinitis, local corticosteroid injection therapy, 923

### Tenidap sodium

- inhibition of activated neutrophil collagenase, 211

- in RA, 204

### Tenosynovitis

- De Quervain's, corticosteroid therapy, 793

- local corticosteroid injection therapy, 923

### Tenoxicam

- pharmacokinetics in synovial fluid and plasma, 751

- in RA, sleep disorders and, 655

### Testosterone undecanoate, in males with RA, 1

### Tetracycline, pleurodesis, for massive pleural effusion in SLE, 1483

### Thrombocytopenia, SLE-associated, intravenous IgG in, 787

### Thrombocytosis, in systemic JRA, serum IL-6 and, 1158

### Thromboxane, renal excretion in RA, cyclosporin A and, 481

### Thymectomy, autoimmune disease and, 916

### Thyroglobulin, anti-thyroglobulin autoantibodies, epitope specificity in Sjögren's syndrome and Hashimoto's thyroiditis, 1585

### Tibia, insufficiency fractures, misdiagnosis as cellulitis, 912

### Tissue factor, in RA synovium, 996

### Tissue inhibitor of metalloproteinase (TIMP)

- in arthritic synovium, 1076

- gene expression, in RA and osteoarthritic synovium, 1094

### Tissue transglutaminase, in RA synovium, 996

### Tissue-type plasminogen activator (tPA), plasma levels, in Raynaud's phenomenon, 255

### Torticollis, septic arthritis of C1-C2 lateral facet joint and, 84

### Toxicity, of NSAIDs, 1353

### Transforming growth factor

- IgG2b induction in RA synovial fluid and, 1461

- inorganic pyrophosphate production in articular cartilage and (pig), 904

### *Tripterygium wilfordii* Hook F (T2), immunosuppression in RA and, 1274

### Tumor necrosis factor, restriction fragment length polymorphisms, in ankylosing spondylitis, 486

### Tumor necrosis factor $\alpha$

- IgG2b induction in RA synovial fluid and, 1461

- in RA synovial tissues and cartilage-pannus junction, 1125

- stimulation of synovial fibroblasts, T cell adhesion and, 1245

## U

### Ultraviolet radiation, UVA, photochemotherapy in RA, 646

### Urate, serum level, progression of gouty changes on radiography and, 1489

### Urokinase-type plasminogen activator

- monocyte-associated proteolytic activity in RA and, 1430

- in RA synovium, 996

## V

### Valvular heart disease, in Ehlers-Danlos syndrome type VIII, 1466

### Vasculitis

- cerebral, associated with moya moya radiologic phenomenon and anti-Ro/SS-A antibodies, 1052

- coronary artery, in relapsing polychondritis, 97

- cutaneous, in Ehlers-Danlos syndrome type VIII, 1466

- temporal artery, Wegener's granulomatosis and, 220

### Venulitis, generalized, fatal pulmonary hypertension and, 228

### Vitamin E, in RA, 1205

### Von Willebrand factor, plasma levels, in Raynaud's phenomenon, 255

## W

### Wegener's granulomatosis, temporal arteritis and, 220

### Work disability

- labor force participation among persons with musculoskeletal conditions (1970-1987), 1361

- RA and household work performance of women, 669

### Workers' Compensation, managing toxicopathic rheumatic disease in current legal climate, 634

Wound healing, postoperative, in methotrexate-treated RA, 146

Wrist, soft tissue rheumatic disorders, local corticosteroid injection therapy, 923

## X

X-linked chronic granulomatous disease, SLE in, 101  
47,XXX karyotype, SLE in patient with, 371

## Y

Yakima Indians, HLA-Dw16 and RA in, 43

*Yersinia* sp.

antigen-specific T cell clones in synovial membrane and synovial fluid of patient with reactive arthritis, 1151  
reactive arthritis, bacterial detection via polymerase chain reaction, 89

Yttrium-90, absorbed dose profile in radiation synovectomy, 1521